

## Review Article

# Modelling the functional genomics of Parkinson's disease in *Caenorhabditis elegans*: *LRRK2* and beyond

Rachael J. Chandler<sup>1</sup>, Susanna Cogo<sup>1,2</sup>,  Patrick A. Lewis<sup>3,4</sup> and  Eva Kevei<sup>1</sup>

<sup>1</sup>School of Biological Sciences, University of Reading, Reading, RG6 6AH, U.K.; <sup>2</sup>Department of Biology, University of Padova, Padova, Via Ugo Bassi 58/B, 35121, Italy; <sup>3</sup>Royal Veterinary College, University of London, London, NW1 0TU, U.K.; <sup>4</sup>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3BG, U.K.

**Correspondence:** Eva Kevei (e.g.kevei@reading.ac.uk)



For decades, Parkinson's disease (PD) cases have been genetically categorised into familial, when caused by mutations in single genes with a clear inheritance pattern in affected families, or idiopathic, in the absence of an evident monogenic determinant. Recently, genome-wide association studies (GWAS) have revealed how common genetic variability can explain up to 36% of PD heritability and that PD manifestation is often determined by multiple variants at different genetic loci. Thus, one of the current challenges in PD research stands in modelling the complex genetic architecture of this condition and translating this into functional studies. *Caenorhabditis elegans* provide a profound advantage as a reductionist, economical model for PD research, with a short lifecycle, straightforward genome engineering and high conservation of PD relevant neural, cellular and molecular pathways. Functional models of PD genes utilising *C. elegans* show many phenotypes recapitulating pathologies observed in PD. When contrasted with mammalian *in vivo* and *in vitro* models, these are frequently validated, suggesting relevance of *C. elegans* in the development of novel PD functional models. This review will discuss how the nematode *C. elegans* PD models have contributed to the uncovering of molecular and cellular mechanisms of disease, with a focus on the genes most commonly found as causative in familial PD and risk factors in idiopathic PD. Specifically, we will examine the current knowledge on a central player in both familial and idiopathic PD, *Leucine-rich repeat kinase 2* (*LRRK2*) and how it connects to multiple PD associated GWAS candidates and Mendelian disease-causing genes.

## Introduction

Parkinson's disease (PD) is a common, progressive and multi-system neurodegenerative disorder, for which there is currently no disease modifying therapeutic. Affecting 2% of the population over 65 [1], PD is clinically characterised by the development of a progressive resting tremor, bradykinesia and rigidity, responsive to dopamine pathway therapeutics [2–4]. Although predominantly considered a movement disorder, debilitating non-motor symptoms of PD are common in affected individuals and heterogeneous in their presence and extent [2,4–6]. These can include hyposmia, sleep disturbances and autonomic dysfunction, leading to postural hypotension, constipation and urinary incontinence [7]. Psychological conditions such as anxiety and depression have a high incidence throughout PD progression [5–7], along with cognitive impairment, with dementia affecting approximately 60% of individuals 12 years post diagnosis [8]. PD is driven by the degeneration of dopaminergic neurons in the *substantia nigra pars compacta*, leading to the cardinal motor symptoms, and neuropathologically distinguished by the accumulation of

Received: 15 February 2021  
Revised: 03 August 2021  
Accepted: 13 August 2021

Accepted Manuscript Online:  
16 August 2021  
Version of Record published:  
31 August 2021

Lewy bodies, protein aggregates mainly composed of fibrillar  $\alpha$ -synuclein [9]. At the point of PD diagnosis,  $\alpha$ -synuclein pathology in the brain is widespread [9], accounting for the diversity and heterogeneity of non-motor symptoms, with an estimated 80% of dopaminergic neurons in the *substantia nigra* lost at the onset of diagnostic motor symptoms [7]. Hence, the development of novel, disease modifying therapeutics to halt or slow the progression of PD is an area of extensive research, underpinned by our understanding of cellular pathways perturbed in PD pathogenesis.


The complex aetiology of idiopathic PD is a rapidly expanding area of research, with a plethora of genetic and environmental factors associated with the lifetime risk of PD development [1,10–12]. Approximately 90% of late adulthood-onset PD cases are idiopathic, defined by the absence of an evident monogenic determinant, while the remainder are familial, showing monogenic, Mendelian patterns of inheritance [13]. In most cases, Mendelian PD is symptomatically indistinguishable from the idiopathic disease [13–15], suggesting a potentially shared pathophysiology. PD causative mutations have been identified in a plethora of genes summarised in Figure 1, many of which converge on common pathways including endosomal sorting, vesicle trafficking, lysosomal and mitochondrial function [16]. However, increasing evidence suggests that familial and idiopathic PD can follow an oligogenic pattern of inheritance, in which variants in a number of key genes result in an increased susceptibility to PD onset [17,18]. About 30% of individuals with PD linked to a pathogenic mutation in a Mendelian PD gene also have a concurrent variant in one or more known PD associated genes [18], potentially accounting for variance in disease progression and penetrance between affected individuals. Additionally in post-mortem studies of individuals affected by idiopathic PD with dementia, 23% had more than one genetic variant in known PD associated genes, compared with 10% in an unaffected control population without PD [19]. Importantly, through functional studies of Mendelian disease genes in a diverse range of *in vitro*, *in vivo* and *in silico* models [20,21], substantial progress has been made in elucidating the molecular mechanisms of neurodegeneration in PD.

Common genetic variants identified through genome-wide association studies (GWAS) targeting increased risk of developing idiopathic PD [22] have improved our understanding of the genetic architecture of PD [23–26]. A recent, comprehensive meta-analysis of PD GWASs identified 90 genomic risk signals at 78 genomic loci associated with increased lifetime risk of PD, accounting for up to 36% of heritable risk for PD [24]. Although a great deal of further research is required to conclusively identify the causative variants of these loci, many of the candidate genes converge upon similar cellular pathways shown to be perturbed in Mendelian cases of the disease, notably endocytic vesicle trafficking [16], lysosomal and mitochondrial function [25].

The burden of multiple, common variants within risk loci, which may be present in a single individual, contribute to a polygenic risk score of lifetime PD development [24]. Importantly, a polygenic risk score does not account for environmental factors, which also impact on PD risk and may therefore not be clinically useful in diagnosis, if considered alone [22]. However, when taken in conjunction with prodromal PD symptoms, polygenic risk scores may help in stratifying groups for clinical trials with enhanced genetic precision for targeting, as novel drugs are developed [22]. Identified genes vary in their effect size upon polygenic risk score depending on their functionality, with common variants in known PD associated genes driving larger effect sizes [22,24]. An additional challenge of determining the effect size of novel GWAS loci upon polygenic risk score is that functional modelling for these genes in the context of PD are frequently yet to be undertaken. Thus, our understanding of the mechanism of action of these novel loci and impact upon risk of PD development is incomplete.

The nematode worm, *Caenorhabditis elegans* (*C. elegans*), provides an excellent model system for understanding underlying disease biology in neurodegenerative conditions [20,27,28] and is a promising candidate for functional dissection of the complex genetic architecture of PD. Between 60–80% of human genes have orthologues in *C. elegans* [29] and its genome was the first of any multicellular organism to be completely sequenced [30,31]. Thus, along with the extensive experimental tools available in this system, it facilitates the generation of simple, *in vivo* gene function models. *C. elegans* have been widely used as a model for ageing [32], with their short lifespan and rapid reproduction rate facilitating straightforward and fast study of this process. *C. elegans* are highly amenable to neurobiology, as they have a fully mapped neural connectome [33,34], in which each neuron is characterised in its neurochemistry, connectivity and functionality, often with attributable behavioural phenotypes to each neural circuit to test [35,36]. Furthermore, the majority of neurotransmitters utilised in neuronal signalling in the human brain, are also produced and utilised in the *C. elegans* neuronal system [30,37,38]. Most Mendelian PD genes have orthologues in *C. elegans* (Table 1) and multiple models for PD have been developed. These have demonstrated substantial functional conservation with their human counterparts and yielded important insights into gene function [20,21].

*C. elegans* present a range of PD relevant behavioural and organismal phenotypes to characterise and test, as outputs of gene function, which range from specific dopaminergic neuron attributable behaviours [36,48–50], *in vivo* microscopy [51], to organismal responses to environmental stressors [35], as summarised in Figure 2. Comprehensive



**Figure 1. The emerging genetic architecture of Parkinson's disease**

Mutations and variants in several genes have been identified to be causal or increase susceptibility to PD. Genes indicated in red, which have a very high or causal link with PD development, show Mendelian inheritance and are rare in the population. Genes indicated in orange confer a greater risk of PD development, but with incomplete penetrance. These genes have been identified through both Mendelian and GWAS studies. The expansion of GWAS targeting idiopathic PD has highlighted a plethora of common alleles, illustrated in yellow. These are very common in the population and confer a heightened susceptibility to PD development. Different PD linked mutations in *LRRK2* confer varying risk of PD development and penetrance. There are protective variants in *LRRK2*, which significantly reduce the risk of PD development, highlighting the central role *LRRK2* may play in PD pathogenesis.

and recent reviews of PD relevant phenotypes in *C. elegans* can be found elsewhere [21,35], and open access databases such as WormBase and WormBook contain extensive, up-to-date information on organism genes, *C. elegans* biology and experimental protocols [52,53]. Functional studies of PD in *C. elegans* have, to date, been undertaken using gene deletions, RNAi silencing and transgenic overexpression of the human protein of interest (Table 1 and Figure 2) [20,54,55], but the development of CRISPR/Cas9 has enabled the introduction of specific point mutations in *C. elegans* orthologues [56], for functional modelling from a new perspective.

In this review, we will evaluate the potential modelling approaches of the functional genetics of PD using *C. elegans*. We angle our focus on the central PD player *LRRK2* and its interplay with Mendelian PD genes such as *VPS35*, which is integral to endosomal function, and the PD hallmark  $\alpha$ -synuclein, along with the consistent GWAS locus and potential new therapeutic target, *RAB29*. The concurrent growth of PD genetics and *C. elegans* technologies, summarised in Figure 3, opens an expansive window for the development of simple *in vivo* models, enabling further

**Table 1** Mendelian Parkinson's disease genes and their *C. elegans* orthologues


PD Patient Phenotype	Mendelian PD Gene	Average Age of PD Onset	Number of Confirmed Pathogenic Mutations	Inheritance	GO Biological Functions Disrupted in PD Gene Functional Models	<i>C. elegans</i> Orthologue	<i>C. elegans</i> Models Reported		
							Deletion	Transgenic Expression	RNAi
Typical PD	<b>LRRK2</b>	58	10	Dominant	Endosomal Network, Endocytosis, Vesicle trafficking, Microtubules, Lysosomal Function, Macroautophagy	<b>lrk-1</b>	+	+	+
	<b>VPS35</b>	50	1		Endosomal Network, Endocytosis, Vesicle trafficking, Lysosomal Function	<b>vps-35</b>	+	-	+
	<b>SNCA</b>	45	4		Lysosomal stressor	-	-	+	-
	<b>PINK-1</b>	35	143	Recessive	Mitophagy	<b>pink-1</b>	+	-	+
	<b>PARKIN</b>	31	14		Mitophagy	<b>pdr-1</b>	+	-	+
	<b>PARK7</b>	58	5		Oxidative Stress Response	<b>djr-1.1</b>	+	-	+
						<b>djr-1.2</b>	+	-	-
Parkinsonism	<b>DNAJC13</b>	67	0	Dominant	Endosomal Network	<b>rme-8</b>	+	-	+
	<b>DNAJC6</b>	Juvenile	1	Recessive	Endocytosis	<b>dnj-25</b>	+	-	+
	<b>ATP13A2</b>	Juvenile	6		Lysosomal Function	<b>catp-5</b>	+	-	+
						<b>catp-6</b>	-	-	+
						<b>catp-7</b>	-	-	-
	<b>SYNJ1</b>	Early-onset	3	Recessive	Endosomal Network, Endocytosis	<b>unc-26</b>	+	-	+
	<b>RAB39B</b>	Early-onset	3	X-linked Recessive	Vesicle Trafficking	<b>rab-39</b>	-	-	+

Mendelian PD genes with clinical data regarding PD patient phenotype, mode of inheritance and average age of onset are shown with the corresponding orthologue genes in *C. elegans*. Data have been obtained from Mendelian PD clinical studies [1,14,39–46]. The number of confirmed pathogenic mutations has been obtained from NCBI ClinVar database [47], using the filtered by mis-sense and pathogenic mutations filters. ClinVar database lists 10 pathogenic variants for LRRK2, however, of these only 7 variants have been clearly shown to be pathogenic, suggested by multiple reports from independent kindreds. *Caenorhabditis elegans* orthologues have been determined using Ortholist2 search of Mendelian PD genes [29]. Existing *C. elegans* models were obtained from reported phenotype data on each orthologue's Wormbase entry. GO Biological Functions have been identified utilising G-profiler. Most Mendelian PD genes have an orthologue in *C. elegans*, the gene function of which has been previously studied through either gene deletion, RNAi silencing, transgenic overexpression of the gene or the combination of these methods.

elucidation of gene function and advancing our understanding of PD pathogenesis.


## The role of LRRK2 in PD and pleiotropy in neurodegenerative disease

Through candidate gene sequencing and recombination mapping in 46 families with autosomal dominant, late-onset PD, seven coding variants in *LRRK2* have been identified to be causative for PD since the first description of mutations in 2004 (Figure 4) [57–60]. Mutations in *LRRK2* are the most common cause of monogenic PD [13], with




**Figure 2. Selected examples of the extensive *C. elegans* toolbox for PD gene functional modelling**

Multiple genetic approaches can be utilised to investigate gene function in *C. elegans*. PD pathology can be investigated in *C. elegans* through *in vivo* microscopy, using established cellular reporters of dopaminergic neuron degeneration,  $\alpha$ -synuclein aggregation, mitochondria network and lysosomal function.



**Figure 3. A Quarter Century of advances in human PD genetics, *C. elegans* technologies and functional modelling of Mendelian PD in *C. elegans***

Timeline of advancements in our understanding of PD genetics, from the identification of the first mendelian PD gene encoding for  $\alpha$ -synuclein in 1997, to the novel and expanding insights recently gleaned through GWAS. Human PD genes are indicated above the timeline and have individual colours assigned to them, with the milestones in *C. elegans* research of this gene or orthologues beneath the timeline indicated with the same colour. Concurrent with the growth of human genetic data in PD, there has been much advancement in *C. elegans* technologies relevant to PD research, illustrated with grey boxes. As a model, *C. elegans* has been pivotal in the development of RNAi technology, whole organism genome sequencing and recently, CRISPR/Cas9 genome editing, enabling the dissection of the effect of point mutations in orthologues. Many of the Mendelian PD genes presented have been studied in *C. elegans* functional models, with promising conservation demonstrated. Some of these are discussed in depth, throughout this review.



**Figure 4. Conservation of domain organisation and amino acid residues between *H. sapiens* LRRK2 and *C. elegans* LRK-1**  
 Human LRRK2 and *C. elegans* LRK-1 share substantial conservation in terms of domain structure, particularly within the catalytic core incorporating the ROC-COR and Kinase domains. The Armadillo domain (ARM), Ankyrin domain (ANK) Leucine Rich Repeats (LRR) and WD40 domain are scaffold regions, facilitating PPIs. Domain information has been obtained from ProSite and Interpro sites, domain visualisation has been generated in DOG1.0 [64]. Sequence alignment has been obtained through analysis of full-length protein sequences with Emboss.001\_Needle, pairwise sequence alignment online tool, Matrix: EBLOSUM62, Gap penalty:12, Extend penalty:2 [65–67]. Key residues, that are mutated and pathogenic in PD (labelled with red), and residues, the synthetic mutation of which causes catalytic ablation with demonstrated functional consequences (highlighted in blue) are conserved in *C. elegans*, with high or similar sequence identity in surrounding residues. Two of the five key autophosphorylation sites found in LRRK2 are also present in LRK-1 (shown with purple labels).

potential emerging roles of the protein in idiopathic PD [61–63]; therefore, it has been intensively investigated for the development of therapeutics [63].

LRRK2 incorporates a Ras-like GTP-ase domain (Ras of complex proteins), known as ROC, with an adjacent C-terminal of ROC, known as COR domain. These are the defining feature of the ROCO protein family, of which LRRK2 is the most studied member. Adjacent to the ROC-COR is a kinase domain [68–70], as shown in Figure 4. LRRK2 also encompasses scaffold armadillo, ankyrin and the eponymous Leucine Rich Repeat (LRR) domains that facilitate protein–protein interactions (PPIs) at the N-terminus and a WD40 terminal domain at the C-terminus [71]. Notably, PD pathogenic mutations are clustered in the catalytic ROC-COR and kinase domain and lead to enhanced kinase activity [72–77], a key molecular hallmark of LRRK2 PD [78], which has attracted great attention from a therapeutic perspective (Clinical Trial ID:NCT03710707 [79], NCT04056689 [80]). Several mutations are located in the ROC domain and disrupt GTP hydrolysis [81–83], thereby increasing the proportion of LRRK2 molecules bound to GTP rather than GDP, enhancing auto and substrate phosphorylation [75,83–88]. The interdependence between GTPase and kinase activities is further supported by evidence that synthetically engineered GTP binding ablation mutations in LRRK2 significantly impair kinase activity *in vitro* [89,90], although this is not reflected in all models [91,92]. LRRK2 acts as a homodimer [93,94], suggesting that the enzymatic core functions via an interdependent mechanism, with the ROC domain activating the kinase domain when in its GTP bound state [68,86]. This is contentious, as in alternative, well conserved bacterial models, LRRK2 monomerization occurs following GTP binding, but is found as a dimer when GTP bound or nucleotide free [95]. In addition, LRRK2 is likely in equilibrium between a monomeric, cytosolic and dimeric, membrane bound form [96]. Intriguingly, PD associated mutations in the ROC-COR domain were proposed to alter LRRK2 dimerization and cellular localisation [91,92]; however, the

detailed mechanisms as to how the GTPase and kinase domain reciprocally cross regulate activity remains elusive [76,86].

The most common LRRK2 mutation associated with PD, G2019S, is located in the kinase domain and causes a modest 2-fold increase in kinase activity and phosphorylation of substrates *in vitro* [77] and *in vivo* [97], while increasing the LRRK2<sup>G2019S</sup> autophosphorylation activity 4-fold [98]. The LRRK2<sup>R1441C</sup> mutation, located in the ROC domain, disrupts GTP hydrolysis, enhancing both substrate phosphorylation and autophosphorylation activity by approximately 3 to 4-fold [89,97,99]. These differences in kinase activity might explain the lifetime risk of PD in LRRK2 mutation carriers, with higher penetrance observed for LRRK2<sup>R1441C</sup> carriers [1,10], although with a later age of onset when compared with LRRK2<sup>G2019S</sup> carriers [1], illustrating that more complex mechanisms may be in action. In addition, while the impact of the LRRK2<sup>G2019S</sup> substitution is restricted to the kinase pocket of LRRK2, any alteration in the GTPase domain is likely to exert broader biochemical and cellular effects on protein function [90].

The majority of individuals with LRRK2 PD present with classical PD symptoms and exhibit variable Lewy body pathology upon post mortem examination [10,57]. Interestingly, all LRRK2 PD cases exhibit significant tau accumulation [57,58,100–102], a pathology observed in some idiopathic PD cases [103], particularly in PD with dementia [104]; however, this is not a diagnostic hallmark of PD upon autopsy [4,9]. Moreover, the tau gene *MAPT* is within a consistent idiopathic PD GWAS locus [24,103], illustrating its potential relevance in idiopathic PD. Lewy bodies and tau have a pleomorphic role in neurodegenerative disease pathology [105,106]. The former are pathognomonic for dementia with Lewy bodies [107], with  $\alpha$ -synuclein found in glial cytoplasmic inclusions in Multiple System Atrophy (MSA) [108] and are found as a secondary protein aggregate pathology in up to half of Alzheimer's disease (AD) cases [109]. Meanwhile, tau is a prominent player in multiple neurodegenerative conditions including AD [110], progressive supranuclear palsy (PSP) [111] and frontotemporal dementia (FTD) [112]; hence, study of LRRK2 with its associated tauopathy and Lewy body aggregation may be applicable to a range of neurodegenerative conditions.

LRRK2 is notable for exhibiting pleiomorphic pathology in neurodegeneration and in the peripheral immune system [113]. In terms of neurodegeneration, variants in the LRRK2 locus have recently been identified through GWAS as candidates for increased survival in the tauopathy PSP [114]. Additionally, LRRK2 is highly expressed in many cell types of the immune system [115] and its expression is increased in the B cells, T cells and CD16+ monocytes of idiopathic PD patients, compared with the unaffected control population [116]. This suggests there may be a mechanistic role for LRRK2 in PD relevant inflammation. Notably, variants in LRRK2 have been observed to increase susceptibility to *Mycobacterium leprae* infection [117], the microbe causative of leprosy, characterised by peripheral neuron damage. Meanwhile, alternative variants in LRRK2 have been shown to increase the risk of Crohn's disease [118], an inflammatory condition of the gastrointestinal tract. This further illustrates that studies of LRRK2 may shed additional insights into wider disease pathophysiology. In recent years, LRRK2 kinase hyperactivation has been implicated in idiopathic PD, while LRRK2 has remained a consistent candidate emerging from idiopathic PD GWAS [22,119–121] suggesting that LRRK2 functional modelling will provide insights into idiopathic disease, a current challenge in PD research.

## LRRK2 as a therapeutic target

LRRK2 is a promising, druggable target for developing a disease modifying therapeutic for PD, with the potential to be applicable in some cases of idiopathic disease presented with LRRK2 hyperactivation [63]. However, upon the onset of diagnostic PD symptoms, disease pathology is already well established. Concurrent with the development of novel therapeutics, early biomarkers for PD and LRRK2 hyperactivation are under extensive investigation, with the aim to enable targeted pharmacological therapies early in disease pathogenesis or at a prodromal stage [122,123].

For over a decade, it has been known that LRRK2 inhibitors targeting kinase activity can protect against PD associated phenotypes driven by LRRK2 phosphorylation, in *in vitro* and *in vivo* models [124]. Inhibitors have been under extensive development, and in pre-clinical models they have abated  $\alpha$ -synuclein mediated neurodegeneration [125,126]. Currently, LRRK2 kinase inhibitors are undergoing early stage clinical trials for safety and efficacy (Clinical Trial ID:NCT03710707 [79], NCT04056689 [80]). Furthermore, splice-switching antisense oligonucleotides (ASOs) targeting LRRK2 have demonstrated that in human patient-derived cells and murine humanised models, LRRK2 levels can be stably reduced, leading to reduced LRRK2-mediated phosphorylation activity [127]. Reduced  $\alpha$ -synuclein inclusions and dopaminergic neuron loss have been observed in the brain of LRRK2-ASO treated mice exposed to  $\alpha$ -synuclein, while peripheral, off target effects of loss of LRRK2 expression were avoided through direct CNS injection of the ASO [128]. ASOs targeting LRRK2 are also entering early stage clinical trials (Clinical trial ID:NCT03976349 [119]), with promising potential. Indeed, ASOs are approved for clinical use in the treatment of

spinal muscular atrophy in over 40 countries [120], illustrating their relevance in neurodegenerative disease therapeutics.

The development of novel, disease modifying therapeutics for PD hinges upon the thorough understanding of perturbed pathways and the identification of druggable targets that arise, often elucidated through gene functional studies. Substantial progress has been made in utilising *C. elegans* as a simple *in vivo* model for PD genes and as a platform for high-throughput screening of chemical and genetic modifiers [21]; however, there is extensive room for further development and understanding.

## The evolutionary conservation of LRRK2 in *C. elegans*

The ROCO proteins are conserved even in simple eukaryotes, such as the slime mould amoeba *Dictyostelium discoideum* [121], in which they were first described. Humans have two LRRK paralogs, LRRK1 and 2, while invertebrate models, such as *Drosophila melanogaster* and *C. elegans* have only one, dLRRK2 and LRK-1 respectively. It has been hypothesised that *LRRK2* arose as a gene duplication event, following the protostome-deuterostome split [129,130]. Studies of evolutionary gene duplications have suggested that splits can lead to sub-functionalisation in which the ancestral gene functions are duplicated into two separate genes [131]. In the instance of LRRK2, if sub-functionalisation has occurred, it may have retained similar functions to LRK-1. However, the functional conservation extent between *C. elegans* LRK-1 and LRRK2 is not yet established. Here, we will discuss current models of LRK-1 function, in contrast with established models of LRRK2 function in order to evaluate its suitability as a model for LRRK2 in PD.


Protein sequence alignments between LRK-1 and LRRK2 demonstrate that many key residues mutated in *LRRK2* PD, or synthetically mutated to ablate catalytic activity, are conserved in *C. elegans* LRK-1 [132,133], implicating potential functional conservation between LRK-1 and LRRK2 (Figure 4). PD associated mutation or enzymatic residue conservation is not illustrated between human LRRK2, when aligned with LRRK1, and differential PPI networks of LRRK1 and 2 suggest divergent cellular function [134,135]. In terms of sequence identity, the extent of conservation between LRK-1, LRRK1 and LRRK2 are broadly similar. Between LRK-1 and LRRK1, there is a 20.9% amino acid identity (35.9% similarity), while between LRK-1 and LRRK2, there is a 20.3% identity (36.3% similarity) [65,136]. LRRK1 and LRRK2 phosphorylate distinct subsets of RAB proteins, downstream effectors of LRRK activity [137], and mutations of LRRK1 lead to a rare bone condition, osteosclerotic metaphyseal dysplasia [138–140], also indicative of divergent functionality. Future modelling of key PD pathogenic LRRK2 mutations and variants in *C. elegans* LRK-1 (Figure 4) may shed light on the extent of functional conservation between *C. elegans* LRK-1 and mammalian LRRK1 and LRRK2.

When contrasted with LRRK2 mammalian *in vitro* and *in vivo* model systems, functional studies of *C. elegans* LRK-1 suggest it is a promising candidate as a LRRK2 model, as extensively detailed in Figure 5 and throughout this review. Here, we will first discuss the role of LRK-1 deletion and humanised LRRK2 transgenic models, followed by insights gleaned from study of LRK-1. This will be succeeded by the *C. elegans* conservation of the RAB29/LRRK2 axis, retromer dysfunction and protein aggregation, pertinently tau and  $\alpha$ -synuclein in modelling LRRK2-linked Parkinson's pathogenesis, with potential implications for modelling the candidate genes of novel GWAS loci.

## The relevance of LRK-1 deletion models for PD

Studies of *LRRK2* function in *C. elegans* have often been limited to *lrk-1* gene deletion, or transgenic overexpression of human LRRK2 on a wild-type nematode background [132,133,141–143]. Deletion models are useful in understanding physiological LRK-1 function, however in the context of understanding the biology of *LRRK2* mutation driven PD, the modelling needs to be extended to the individual gene variants with proven, or possible pathogenicity. PD-linked mutations in *LRRK2* have consistently been shown to act through a toxic gain of function mechanism, in which phosphorylation activity of LRRK2 is increased [78]. Human genetic studies have illustrated that there are individuals with heterozygous loss of function variants in *LRRK2* [144], leading to an approximately 50% reduction in LRRK2 protein levels [144,145]. These individuals do not present with PD and have no significant health complications [145]. This suggests that in humans there could be compensatory mechanisms for LRRK2 function reduction, and that drug delivered kinase inhibition, or application of ASOs in therapeutics may not be deleterious. However, in pre-clinical rodent and non-human primate animal models, LRRK2 inhibitor treatment presented on-target side effects in the lung, showing abnormal accumulation of lysosomal related organelles known as lamellar bodies [146]. Encouragingly, this phenotype was reversible [146], and early stage clinical trials of LRRK2 inhibitors have so far showed safety and tolerability [79,80]. Pre-clinical *in vitro* models illustrate that LRRK2 inhibition does not significantly affect LRRK1 phosphorylation activity, supporting their distinct structure and function [147]. In the context of *C. elegans*, deletion mutant and RNAi loss of function *lrk-1* models would not provide an orthologous tool to





**Figure 5. Functional roles of LRRK2, contrasted with *C. elegans* LRK-1**

The summary of key pathways and functions implicated in LRRK2 PD (shown in the light blue boxes). Underlying studies describing LRRK2 functions in patient studies, mammalian, and *in vitro* models are shown for each function in dark orange boxes. The relevant *C. elegans* pathways are detailed in the light orange boxes. These demonstrate a promising functional conservation between *C. elegans* LRK-1 and mammalian LRRK2, augmenting LRK-1's relevance for further functional modelling in PD. Further details of all examples detailed here are discussed throughout the main body of text.

modelling the PD gain of function *LRRK2* mutations. Furthermore, *C. elegans lrk-1* deletion models do not show impaired dopaminergic phenotypes and behave similarly to wild-type [141], supporting the human genetics findings [145].

## Insights from transgenic expression of LRRK2 in *C. elegans*

Using humanised *C. elegans* models, through overexpressing human LRRK2 in wild-type and PD mutant form, it is possible to model gain of function mutation effects [76]. However, caution is needed when interpreting data, as little is known about the background phosphorylation activity and potential interplay, dimerization and functional redundancy of wild-type *C. elegans* LRK-1, when human LRRK2 is co-expressed. Adult *C. elegans* with a wildtype *lrk-1* background, expressing LRRK2<sup>G2019S</sup> and LRRK2<sup>R1441C</sup> in the dopaminergic neurons, alongside a dopaminergic neuron specific GFP reporter, exhibit significantly reduced GFP fluorescence by day 3 of adulthood, indicative of dopaminergic neurodegeneration [148]. This has been replicated in further studies, illustrating that these models have a robust, PD associated phenotype, relevant to LRRK2 modelling [76,149]. Often, rodent models do not recapitulate key PD hallmarks in terms of neuropathology [150]; however, viral-mediated PD mutant LRRK2 overexpression induces dopaminergic neuron loss [151,152]. The development of PD relevant phenotypes and neuropathology in rodents occurs over several months, while *C. elegans* have an advantage in speed, sample size and exhibition of robust phenotypes within days.

Furthermore, *C. elegans* are highly amenable to environmental toxin assays and drug screens to evaluate the interplay with transgenic expression of human proteins of interest [153,154]. *C. elegans* strains overexpressing the PD associated LRRK2<sup>G2019S</sup> and LRRK2<sup>R1441C</sup> mutant proteins in neurons show reduced survival in response to oxidative stress induced by the environmental toxins rotenone and paraquat, widely used in toxin-based models of PD [155], when compared with animals expressing wild-type LRRK2 [142,148]. However, these studies did not examine whether protection was kinase dependent, through LRRK2 inhibition, or expression of kinase inactive LRRK2. Notably, *C. elegans* overexpressing wildtype LRRK2 show enhanced survival to oxidative stress and increased lifespan

compared with non-transgenic wild-type animals. This suggests a LRRK2-driven protective effect, while deletion, or RNAi silencing of *lrk-1* in non-transgenic lines have shown a significantly reduced survival under these conditions [148,156]. Overexpression of LRK-1 is yet to be utilised in oxidative stress assay, so it is currently unknown whether this would have a similar effect to heterologous expression of LRRK2. These results suggest that PD mutant LRRK2 has a reduced efficacy in oxidative stress protection in *C. elegans*. However, the expression of these pathogenic LRRK2 variants in wildtype *C. elegans* background provides enhanced stress resistance compared with wild-type, non-transgenic *C. elegans*. This suggests that examination of the role of endogenous LRK-1 mutant proteins, with physiological expression levels, might provide better understanding of how these mutations impact survival of the organism, or the dopaminergic neurons. Nevertheless, this illustrates LRK-1's global role in oxidative stress survival, which may not be neuronal specific or restricted to neurons.

Additionally, the transgenic lines discussed above have been utilised as *in vivo* models to test early LRRK2 inhibitors LRRK2in1 and TTT-3002 [157,158]. Dopaminergic behavioural phenotypes and neurodegeneration observed in vehicle treated nematodes expressing LRRK2<sup>G2019S</sup> or LRRK2<sup>R1441C</sup> [76] are rescued following treatment with any of the two LRRK2 inhibitors [76]. However, the effect of LRRK2 inhibitors upon endogenous LRK-1 is unknown, and molecular readouts for LRK-1 phosphorylation activity remain to be identified. Similar effects in nematode behaviour, dopaminergic neurodegeneration and LRRK2 phosphorylation activity were demonstrated in a recent study utilising allosteric inhibition of LRRK2 kinase activity by vitamin B12 in LRRK2<sup>G2019S</sup> expressing lines [149], in support of the robust, relevant phenotypes and promise of *C. elegans* in pharmacological assays.

The use of transgenic human LRRK2 expressing *C. elegans* models have contributed to our understanding of LRRK2 function, while studies of LRK-1 suggest it may share functional conservation with LRRK2. Further characterisation and understanding of *C. elegans* LRK-1 function may shed further insight into LRRK2 mediated pathology from a novel model angle.

## **LRRK2 and *C. elegans* LRK-1 functionality in vesicle trafficking, endocytosis and WNT signalling**

Data obtained upon transgenic expression of *C. elegans* LRK-1 generally supports the hypothesis that it may share some functional conservation with LRRK2. In 2007 *C. elegans* LRK-1 was suggested to have a role in regulating synaptic vesicle localisation to the dendrites of neurons, through modulating protein sorting in the Golgi in a kinase activity dependent manner [133], while deletion of LRK-1 leads to increased sensitivity to tunicamycin induced endoplasmic reticulum stress [132]. Accordingly, enrichment at Golgi and the regulation of intraneuronal protein sorting through this network has also been reported in studies of LRRK2 in rat cortical neuron cultures *in vitro*, and in *Drosophila melanogaster* and rodent models, *in vivo* [159]. Expression of *C. elegans* LRK-1<sup>K1726A</sup> and LRK-1<sup>I1877T</sup> mutant proteins in the *C. elegans* *lrk-1* deletion mutant, (equivalent missense point mutations of the synthetic kinase ablation LRRK2<sup>K2014A</sup> and PD associated kinase hyperactive LRRK2<sup>L2020T</sup>, respectively) has demonstrated that kinase activity of LRK-1 is crucial to its function in determining polarised vesicle localisation in axons of *C. elegans* sensory neurons, suggesting shared conservation in enzymatic activity and functionality between LRK-1 and LRRK2 [133,160]. LRRK2 kinase activity has recently been shown to be essential in modulating axonal transport, with abnormal activation of kinesin *in vitro* and *in vivo* in PD LRRK2<sup>G2019S</sup> mutant models [161]. Interestingly, in the 2007 study of LRK-1, localisation of synaptic vesicle proteins was shown to depend on the *C. elegans* protein UNC-101, an orthologue of the clathrin adaptor protein AP-1 [160] involved in vesicle trafficking from the Golgi to endosome. Clathrin adaptor proteins are integral to vesicle transport processes, including clathrin-mediated endocytosis (CME), a process also regulated by LRRK2 [162]. Alterations to the CME process have been recognised in PD [163–165] and other neurodegenerative conditions [166,167], implicating potential functional overlap in the *C. elegans* model.

WNT/ $\beta$ -catenin signalling is an essential pathway in dopaminergic neurogenesis during development and also contributes to synapse formation and neuroprotection during ageing [168]. As PD is caused by the loss of dopaminergic neurons, the WNT/ $\beta$ -catenin pathway is of great interest in the development of disease modifying therapeutics targeting neurogenesis [168]. Importantly, LRRK2 plays key roles in the WNT signalling pathways [78,169–171]. LRRK2 modulates axonal development through inducing phosphorylation of the WNT receptor Frizzled3, a component of the planar cell polarity (PCP) pathway in mice [169], with both loss of function and kinase overactive LRRK2 mutants presenting axon guidance defects. Likewise, in *C. elegans* the WNT signalling pathways modulate neuronal development [172–174]. Interestingly, expression of the *C. elegans* LRK-1<sup>G1876S</sup> (the equivalent of human pathogenic LRRK2<sup>G2019S</sup>) in wild-type, or *lrk-1* deletion mutant background, revealed significant defects in canal-associated neuron development [132]. Furthermore, in an RNAi screen targeting endogenous genes in wildtype *C. elegans* lines

overexpressing human LRRK2<sup>G2019S</sup>, endogenous nematode WNT signalling pathway components and axon guidance genes had the largest effect sizes in determining dopaminergic neuron survival [175]. Thus, this shared phenotype of impaired neuronal development and survival through WNT pathways between transgenic *C. elegans* LRRK-1 and vertebrate LRRK2 models further strengthens the conserved roles of LRRK-1 and LRRK2.

## The shared interactome of LRRK2 and *C. elegans* LRRK-1

Comparative study of LRRK-1 and LRRK2 interactomes further supports functional conservation and it might provide another strategy to identify candidate pathways as novel therapeutic targets [71]. LRRK2 has been shown to bind the BAG2-HSC70 chaperone complex, acting as a chaperone for LRRK2 [176]. In *C. elegans*, UNC-23 and HSP-1, the orthologues of BAG2 and HSC70 respectively, interacts with LRRK-1, highlighting existing conservation of protein interactions [176]. Further functional studies have illustrated that UNC-23 mediates Golgi localisation of LRRK-1 in co-operation with HSP-1, and *unc-23* deletion mutants phenocopy the defects in synaptic vesicle localisation [176], as seen in *lrk-1* deletion mutants [132,133,176]. This suggests that UNC-23 and LRRK-1 function together in synaptic vesicle localisation.

LRRK2 has an extensively characterised interactome; a stringent search through PINOT, a resource for obtaining quality controlled PPIs in humans and *C. elegans* [177], indicated 1440 interactor hits for LRRK2, replicated with multiple studies and methods (July 2021). In contrast, the LRRK-1 interactome is poorly characterised, with only few interactors noted. Due to the existing conservation of interactions and of the molecular and cellular function between LRRK-1 and LRRK2, *C. elegans* could provide an excellent tool to drive interactome-based functional studies. These could be investigated in the context of the ageing organism, including environmental and genetic PD risk factors, utilising the high-throughput nature of this model to assess the efficacy of genetic and chemical disease modifiers.

## The role of Parkinson's disease GWAS candidate risk gene *RAB29* in LRRK2 and idiopathic PD

RAB proteins are a superfamily of small GTPases, with diverse regulatory roles in vesicle formation, trafficking and endosomal transport. A subset of these RABs are key effector substrates of LRRK2 phosphorylation [178]. *RAB29*, also known as *RAB7L1*, has been a consistent PD GWAS hit [24] and the *RAB29* protein has been shown to act upstream of LRRK2 [179], while *RAB3*, *RAB5*, *RAB8*, *RAB10*, *RAB12*, *RAB35* and *RAB43* have been demonstrated to be downstream effector substrates regulated by LRRK2 phosphorylation [180]. *RAB29* has been stratified through unbiased LRRK2 PPI arrays as a candidate risk gene, which may bridge the gap between familial *LRRK2* and idiopathic PD [159,179,181]. Thus, our understanding of the mechanisms of both *LRRK2* and idiopathic PD may be furthered by functional studies of *RAB29*.

*RAB29* has been demonstrated to be a selective master regulator of LRRK2, acting upstream and leading to LRRK2 kinase recruitment, localisation and activation on the Golgi membranes, via binding of *RAB29* to LRRK2s ankyrin repeat domain [179,182,183], with resultant increased LRRK2 kinase activity leading to changes in the trans-Golgi network morphology [184]. However, in another study *RAB29* knockout had no impact on basal LRRK2 phosphorylation activity [185], suggesting a potentially more complex mechanism in LRRK2 modulation and PD pathogenesis. Furthermore, *RAB29* is also a substrate of LRRK2 in human HEK293 cells; LRRK2 with kinase overactive PD mutations LRRK2<sup>R1441C</sup>, LRRK2<sup>Y1699C</sup> and LRRK2<sup>G2019S</sup> present a 4-fold increase of LRRK2 mediated phosphorylation of *RAB29* [178], suggesting interdependent regulation between these two proteins. Other key substrates of LRRK2 are *RAB8A* and *RAB10*, with *RAB8A* shown to accumulate at the trans-Golgi network following *RAB29* mediated LRRK2 recruitment [182]. Furthermore, upon stress induced lysosomal enlargement, LRRK2 is targeted to the lysosomal membranes via *RAB29* [183]. This leads to an accumulation of *RAB8A* and *RAB10*, which attenuates the enlargement of lysosomes, essential for maintaining their integrity and function [183]. Thus, *RAB29* is integral to LRRK2 biology and function, further highlighting the need to develop our understanding of the pathways in a range of models.

## The conservation between *RAB29* and *C. elegans* orthologue, *GLO-1*

*C. elegans* has an orthologue for *RAB29*, *glo-1*, which shows conservation in its function in the endolysosomal transport pathway [186]. A coding variant *RAB29*<sup>K157R</sup> has been detected in an idiopathic PD patient [187], however its pathogenicity, as well as its mechanism of action is unconfirmed. This variant position is conserved in *C. elegans* *GLO-1* and is located within the G5 loop, involved in binding of small G-proteins to nucleotides [71,188]. Importantly, *C. elegans* *GLO-1* has been shown to act upstream of *C. elegans* LRRK-1 [189], congruent with studies of human LRRK2, further suggesting it may be relevant for further functional modelling of *RAB29*. *GLO-1* is also the *C. elegans*

orthologue for the closely related human RAB32 and RAB38, and it is most similar to these proteins in terms of protein sequence identity [29]. GLO-1 shares 45.9% and 46.1% sequence identity with RAB32 and RAB38 respectively, while with RAB29 it shares a 40.7% identity [65,136]. Functional studies of GLO-1 have demonstrated that it shares conservation with all three RAB proteins to varying extents. *In vivo* model organisms do not always show exact orthologue conservation with the human gene of interest. For example, mouse models display significant differences in biology and biochemistry of LRRK2 when compared with human [150]. Despite this, much useful information has been gleaned through functional modelling of LRRK2 in mice [128,151,152], which can be contrasted or supported by consistent findings in alternate *in vivo*, *in vitro* and *in silico* models, along with findings reported in studies of PD patients. Thus, *C. elegans* GLO-1, when taken in conjunction with findings in other models, will be a useful model for further understanding RAB29 function, along with shedding insight into its close counterparts RAB32 and RAB38.

GLO-1 may not just be a potential functional model with relevance to PD, as *RAB29*, *RAB32* and *RAB38* have been highlighted as genes of interest in various neurodegenerative conditions. Functional studies of *RAB29* in the presence of *C9orf72* hexanucleotide repeat [190], causative of amyotrophic lateral sclerosis with FTD (ALS-FTD), have illustrated its role in vesicle trafficking [191]. Additionally, *RAB38* has been identified as a significant GWAS hit in a behavioural variant subtype of FTD [192], while *RAB32* has been associated with ER stress and mitochondrial dysfunction in multiple sclerosis [193]. This illustrates that this small sub-group of RABs may play an important role in the maintenance of neuronal health and an *in vivo* reductionist model of their functions focusing on GLO-1 may be applicable to further research areas.

### The LRK-1/GLO-1 interplay in *C. elegans*

Congruent with the human RAB29/LRRK2 axis, in *C. elegans* both endogenous LRK-1 and neuronally expressed human LRRK2 on a *lrk-1* deletion background have been shown to act downstream from GLO-1 in axon termination [189]. Notably, key residues of RAB29, routinely utilised to synthetically ablate or constitutively activate its GTPase function *in vitro* [190], are conserved in *C. elegans* GLO-1. On the other hand, key LRRK2 phosphorylation target sites T71 and S72 of RAB29 [194] are not conserved. GLO-1 and LRK-1/LRRK2 converge to regulate axonal morphology, highlighting their importance in the nematode central nervous system, and like RAB29 and LRRK2, they have lysosomal roles [189]. In motor neuron axons, GLO-1 and LRK-1 act to modulate endo-lysosomal trafficking or endo-lysosomal maturation, suggesting similar functions to their human counterparts [189]. Transgenic expression of PD mutant LRRK2<sup>G2019S</sup> or LRRK2<sup>R141C</sup> in *lrk-1* deletion mutants efficiently suppresses the axonal abnormality phenotype exhibited in *lrk-1* or *glo-1* deletion mutants [189], suggesting high functional conservation. However, the effect of human RAB29/32/38 expression in *glo-1* deletion mutant background was not investigated, nor was the Golgi localisation of both proteins [189]. Furthermore, the effect or presence of LRK-1/LRRK2 mediated phosphorylation of GLO-1 was not investigated [189], as robust phosphorylation readouts have not been developed for PD relevant orthologues in *C. elegans*. This highlights the need for additional studies to further assess the LRK-1/GLO-1 mechanistic conservation with the comparatively better understood LRRK2/RAB29 interplay.

### The relevance of RAB32 and RAB38 in understanding RAB29 and LRRK2 function

Functional studies of human *RAB32* and *RAB38* implicate some shared pathways with *RAB29*, augmenting the relevance of *glo-1* for further study. RAB32 and RAB38 have been demonstrated to act co-operatively to regulate lysosomal biogenesis and modulation of lysosome-related organelles (LROs) [195]. In *C. elegans*, GLO-1 modulates the biogenesis of LROs, which are intracellular compartments for storage, sharing some characteristics but coexistent with conventional lysosomes [186,196]. Furthermore, human RAB32 and RAB38 co-ordinate lysosomal biogenesis through the clathrin adaptor protein AP-3 [195], which is a known effector substrate of LRRK2, acting downstream from RAB29 [189]. Likewise, studies of GLO-1 have identified modulation of LRO biogenesis through APB-3, the *C. elegans* orthologue of AP-3, via *C. elegans* LRK-1 [197], mirroring the human pathway [189]. Additionally, nematodes with deletion of *glo-1* or *apb-3*, or double deletion mutants of these genes, show decreased LRO biogenesis [189], suggesting convergent biology and importance in this function, as shared in the RAB32 and RAB38 interplay with AP-3. These mutual processes, pathways and interactors suggest that GLO-1 shares high functional conservation with RAB32 and RAB38.

Similarly to RAB29, RAB32 and RAB38 also share convergent biology with LRRK2, although their mechanisms of interaction may differ. RAB32 and RAB38 have been shown to mediate phagosome restriction of intracellular

pathogens, notably *Mycobacterium leprae*, the causative agent of leprosy [198]. Interestingly, single-nucleotide polymorphisms (SNPs) in *LRRK2* have been identified through GWAS as predisposing towards leprosy [117], and a polymorphism in *RAB32* [199] has also been associated with disease susceptibility, implicating potential shared pathways in the immune response between *LRRK2* and *RAB32* and *RAB38*. It is currently unclear whether these immune pathways also contribute to PD pathogenesis [200]. However, it has been hypothesised that PD associated mutations in *LRRK2*, prevalent in multiple human populations [201], may confer greater immunity to selected infectious diseases. This may have led to a balanced selection of *LRRK2* PD mutations, resulting in antagonistic pleiotropy, with potential advantageous roles of mutation in immunity, but increased risk of PD development in later life [113,202].

*LRRK2* physically interacts with *RAB32* and *RAB38* through its armadillo domain [203], convergent with the *LRK-1* and *GLO-1* interaction [189]. Furthermore, *RAB32* and *RAB38* bind to sortin-nexin 6 (*SNX-6*), a transient subunit of the retromer complex, affecting retromer dependent Golgi trafficking [204]. Recent studies have demonstrated that *LRRK2*, bound to trans-Golgi localised *RAB29*, interacts with the GARP complex, stabilising syntaxin-6 and promoting retrograde transport to the trans-Golgi network in a kinase dependent manner [205]. Importantly, syntaxin-6 and all GARP subunits are conserved in *C. elegans* and RNAi knockdown of GARP subunits in *C. elegans* expressing human *LRRK2*<sup>G2019S</sup> in the dopaminergic neurons [141] induces dopaminergic neurodegeneration [205]. This proposed functional convergence of *RAB29*, *RAB32* and *RAB38* at the trans-Golgi network, with influences on trafficking and *LRRK2* interaction suggest that *GLO-1* may have retained similar functions of its three evolved human orthologues and may therefore be useful in gaining further mechanistic insight into the events linking these proteins to neurodegeneration.

## Convergence of *LRRK2* with *VPS35* linked Mendelian Parkinson's disease

A mutation in Vacuolar Protein Sorting 35, *VPS35*<sup>D620N</sup>, was identified in 2011 in a small number of families with late onset, autosomal dominant PD, showing similar symptomatic presentation to idiopathic PD [206–208]. *VPS35* is an integral subunit of the retromer complex, implicated in retrograde transport between the endosomes and the trans-Golgi network [209]. *VPS35* and its link with the retromer was first described in the unicellular *Saccharomyces cerevisiae* [209–211]. *C. elegans* has a well conserved, direct *VPS35* orthologue, *vps-35* [212]. Interestingly, *VPS35*<sup>D620N</sup> has been shown to enhance *LRRK2* kinase activity 6-fold *in vitro*, in CRISPR engineered murine fibroblasts and neutrophils isolated from PD patients carrying *VPS35*<sup>D620N</sup> [99]. This suggests an interplay between *LRRK2* and the retromer in PD, a plausible hypothesis for the molecular mechanism of *VPS35*<sup>D620N</sup> PD, further highlighting the roles of *LRRK2* and the endosomal network in neurodegeneration.

Studies conducted in *C. elegans* thus far have demonstrated that *VPS-35* and the retromer have a role in modulating WNT signalling, determining neuronal migration during development [172,173,213–215]. The role of *VPS35* in WNT signalling is conserved in other invertebrate models, such as, but also in mammals as observed in cell culture studies [215,216], suggesting maintained functional conservation through evolution. Recently, heterozygous *VPS35*<sup>D620N</sup> mouse models have been reported to display WNT/ $\beta$ -catenin signalling dysfunction [217]. The potential pathogenic perturbation of the WNT signalling pathway [217], converging with its impairments illustrated in the *LRRK2* PD models [78], implicates WNT signalling as a core process with relevance to PD pathogenesis. In *C. elegans*, *VPS-35* has been implicated in trafficking of the nematode orthologue of the excitatory AMPA glutamate receptor, *GLR-1*. Deletion of *vps-35* leads to a significant reduction in the number of *GLR-1* puncta on the post-synaptic surface of ventral nervous cord dendrites and suggests a role for the retromer in *GLR-1* recycling [218]. Coherently, in iPSC neuronal cultures derived from people with *VPS35*<sup>D620N</sup> PD, AMPA receptor trafficking was dysregulated and receptors were mislocalised [219]. This shared role between *C. elegans* *VPS-35* and its human orthologue suggest retained functional conservation through evolution.

## The role of retromer dysfunction in tauopathies

Similarly to *LRRK2*, *VPS35* has been associated with tauopathies in *in vivo* and *in vitro* modelling [220,221]. It is currently unclear whether individuals with *VPS35*<sup>D620N</sup> PD exhibit typical  $\alpha$ -synuclein pathology, as due to the rarity of mutations in this gene autopsy studies to date have been very limited [222]. In 2008, a post mortem study was undertaken with one individual from a Swiss family with multi-generational PD, who was later identified as a *VPS35*<sup>D620N</sup> carrier [8]. Key PD relevant brain areas were not analysed, but  $\alpha$ -synuclein pathology was not observed [8]. Hence, additional studies to obtain further insight into  $\alpha$ -synuclein and tau pathology are required. *In vivo* murine models with *VPS35*<sup>D620N</sup> endogenously knocked in exhibit progressive neurodegeneration driven by tauopathy [220], while

retromer has been shown to modulate the lysosomal clearance of tau *in vitro* [221]. The evidence of VPS35<sup>D620N</sup> resulting in enhanced LRRK2 kinase activity [99] further suggests that tau pathology could be present in VPS35<sup>D620N</sup> PD, as tauopathy is a hallmark of LRRK2 PD [102]. Additionally, kinase overactive LRRK2<sup>G2019S</sup> has been demonstrated to enhance neuronal transmission of tau in mouse models [152]. Tau, a key protein in AD and FTD, is a PD GWAS locus and has been observed in approximately 50% of PD patients post-mortem, illustrating the relevance of functional study of LRRK2 for further mechanistic insights potentially applicable to a range of neurodegenerative conditions.

Like tauopathies, retromer dysfunction has been implicated in multiple neurodegenerative conditions, suggesting potential common perturbed pathways and an essential role in neuronal function. In AD autopsy studies, microarrays have illustrated that retromer is depleted in the hippocampus, within the dentate gyrus and entorhinal cortex, a region in which AD pathology is initiated [223]. Further mechanistic studies have shown that retromer facilitates the trafficking of amyloid precursor protein (APP) through sortilin binding within the retromer, thus retromer deficiency leads to APP accumulation and cleavage to pathogenic  $\beta$ -amyloid [224], a driver of AD pathogenesis [225]. Thus, further study of the retromer in the well-conserved *C. elegans* model may shed further insight into multiple pathologies.

### Modelling tauopathies in *C. elegans*

*C. elegans* have a tau-like orthologue, *ptl-1* [226,227] and multiple evidence suggests that this protein may cover essential roles in maintaining neuronal integrity through the lifespan when expressed at basal levels [228]. Loss of *ptl-1* is not rescued by expression of human tau isoforms [228], suggesting potentially limited functional conservation between *ptl-1* and human tau. Multiple studies have used transgenic expression of human tau isoforms, investigating the impact of overexpression of wildtype or pathogenic mutant tau in *C. elegans*. Overexpression of wild-type tau in *C. elegans*, or neuronal expression of A152T mutant tau [229], a risk factor for FTD, PSP and atypical tauopathies [112,230] have been demonstrated to induce neuronal dysfunction [231]. Expression of tau<sup>A152T</sup> in *C. elegans* leads to impaired associative memory, compared with animals expressing wildtype tau [232], and this may be explained by differential impacts on retrograde axonal transport [232], of which the retromer is a central component. The emergence of tau as a contributor to LRRK2 and VPS35 linked PD, the emerging aetiological overlap with the tauopathies and the existence of ready to use tauopathy models in *C. elegans*, provides further opportunities for functional studies and modifier screens of tau pathology, with impacts on multiple neurodegenerative conditions.

### Modelling $\alpha$ -synuclein pathology in *C. elegans* to dissect PD gene function

The first gene to be directly implicated in inherited PD was the *SNCA* gene on chromosome 4 [233]. In 1997, a missense coding variant in *SNCA* (A53T) was found to segregate with PD and dementia in a large family of Greek and Italian origin, the Contursi kindred [233]. Soon after,  $\alpha$ -synuclein, the protein product of *SNCA*, was identified as the major constituent of Lewy bodies [166]. The aggregation propensity of  $\alpha$ -synuclein and its involvement in neurodegenerative diseases had already been reported, albeit without being recognised as  $\alpha$ -synuclein, as it had previously been associated with the non-amyloid component of plaques in AD patients [234], who frequently develop Lewy bodies [109,235]. Since 1997, six *SNCA* missense mutations, as well as gene duplications and triplications have been linked to dominantly inherited PD and dementia, suggesting that an increase not only in the aggregation tendency but also in the expression level of  $\alpha$ -synuclein can induce toxicity [236]. More recently, the advent of GWAS revealed that the *SNCA* locus is among the major determinants of PD predisposition in the general population [237], with variability in common risk loci contributing to the polygenic risk of lifetime PD development [16,24,107,238,239]. These genetic findings have driven functional research, supported by the evidence that *SNCA*, as many others, is a pleiotropic PD gene and that PD follows an oligogenic pattern of inheritance [18,240]. A key unanswered question therefore is, to what extent interplay between  $\alpha$ -synuclein and other PD proteins contribute to the aetiology of PD [241–245].

*C. elegans* do not possess an orthologue of *SNCA*; however, multiple *C. elegans* models have been generated expressing wild-type or mutant human *SNCA* as a transgene, in muscles, neurons or dopaminergic neurons [246,247]. These have been illustrated to recapitulate PD hallmarks of dopaminergic neurodegeneration [155,246,247] and have been employed to study a diverse range of PD relevant pathways, shedding insights into PD pathology. These studies have been discussed in depth in a recent comprehensive review, by Gaeta, Caldwell and Caldwell [248], therefore they will not be extensively covered here. RNAi screens, utilising  $\alpha$ -synuclein overexpressing *C. elegans* models, have

demonstrated that multiple PD relevant genes, such as orthologues of *PINK-1*, *PARKIN*, *ATP13A2* and *DJ-1*, identified in Mendelian familial studies are modifiers of  $\alpha$ -synuclein pathology [249]. This suggests promising pathway conservation, illustrating the great potential to dissect the mechanisms of PD relevant genes, in conjunction with transgenically expressed  $\alpha$ -synuclein in *C. elegans*.

## The interplay of LRRK2/LRK-1 in $\alpha$ -synuclein transgenic models


Many pathways linking  $\alpha$ -synuclein and LRRK2 have been suggested, including cytoskeletal dynamics, ER/Golgi transport, mitochondrial homeostasis and functionality of the degradative systems, leading to the hypothesis that the use of LRRK2 inhibitors might be beneficial in the treatment of synuclein pathology [250,251]. Lack or inhibition of LRRK2 kinase activity or LRRK2 deletion can mitigate neurodegeneration observed in rats after transduction of human  $\alpha$ -synuclein via adeno-associated viral vectors (AAVs) [125,126,252]. Indeed, AAVs, together with lentiviral vectors, have been extensively exploited to deliver wild-type and mutant human  $\alpha$ -synuclein to the *substantia nigra* of rodents and primates, where they lead to Lewy body formation and neurodegeneration. Conversely, overexpression of the wild-type or mutant human  $\alpha$ -synuclein in rodents does not correlate with pathological aggregate formation and degeneration of dopaminergic neurons in the *substantia nigra* [253]. However, expression of human  $\alpha$ -synuclein in the invertebrate models *D. melanogaster* and *C. elegans* recapitulates the major PD hallmarks such as impaired dopaminergic behaviour and neurodegeneration despite the lack of an orthologue [179,244].

Similar studies of  $\alpha$ -synuclein propagation with regard to LRRK2 have been undertaken *in vivo* in rodent models and *in vitro* human derived SH-SY5Y cultures, and contrasted with *C. elegans* LRK-1 [252]. Interestingly, *lrk-1* deletion mutant *C. elegans* shows reduced aggregation of  $\alpha$ -synuclein, expressed in the muscle [252]. In the same study, this phenotype was recapitulated in the brain of *LRRK2* knockout rats, injected with AAV vectors of recombinant human  $\alpha$ -synuclein. These animals showed significantly reduced number of axons immunoreactive for  $\alpha$ -synuclein at 12 weeks [252], consistent with LRRK2 inhibitor studies [125,126]. In a concurrent *in vitro* human SH-SY5Y culture study, this phenotype was determined as kinase activity dependent, with *LRRK2*<sup>G2019S</sup> enhancing  $\alpha$ -synuclein propagation, through RAB35 phosphorylation, a mechanism demonstrated to be conserved in *C. elegans* [252]. Expression of a constitutively active RAB35 in the *lrk-1* deletion mutant reversed the phenotype of reduced  $\alpha$ -synuclein aggregation [252], further illustrating that key mechanisms and pathways in PD pathogenesis are readily modelled in *C. elegans*, despite the simplicity and evolutionary differences of the system.

However, deletion models of PD orthologues, when used in conjunction with  $\alpha$ -synuclein expression still need to be approached with caution. A study developing a *C. elegans* model for neuron-neuron propagation of  $\alpha$ -synuclein *in vivo* demonstrated that RNAi silencing of PD orthologue genes, including *lrk-1*, *pdr-1*, *pink-1*, *vps-35*, resulted in increased  $\alpha$ -synuclein propagation between neurons [254]. Furthermore, more complex mechanisms may be at play, as *lrk-1* expression at the mRNA level has been shown to significantly increase in nematodes expressing  $\alpha$ -synuclein in the muscle in the presence of the apoptosis inducer wedelolactone [255] and the flavonoid tannin [256]. Both of these have been demonstrated to reduce  $\alpha$ -synuclein aggregation in *C. elegans* muscles. Dysregulation of *LRRK2* mRNA expression has been described in post-mortem studies of individuals with idiopathic and *LRRK2*<sup>G2019S</sup> PD [257]. However, these convergences and inconsistencies in *C. elegans*, with regards to the  $\alpha$ -synuclein/*LRRK2* interplay, further highlights the need to develop more precise genetic models of *LRRK2* pathology in *C. elegans*, rather than depending solely on deletion and RNAi silencing studies.

## LRRK2 and beyond: The potential of *C. elegans* for functional modelling of Parkinson's disease GWAS candidate genes

The past two decades have witnessed a seismic change in our understanding of the genetic contribution to the aetiology of PD, culminating most recently in the 2019 meta-analysis of PD GWAS, identifying 90 risk loci for PD, that account for up to 36% of PD heritability [24]. In OrthoList2, a database mapping human genes to their *C. elegans* orthologues [29], 64 of the identified genes have direct orthologues in *C. elegans*, detailed in Figure 6. Considering the increasing speed in dissecting the genetic component of PD and the requirement for rapid and robust functional validation, new models are now required to introduce multiple mutations in a single background and study their interplay. Such a scenario is difficult to achieve in rodents, while *C. elegans* possess the optimal feasibility in terms of genetic manipulation, for the generation of oligogenic models, along with RNAi and chemical modulator screening to investigate the impact of genetic and environmental factors. Genome-wide RNAi screens are powerful, but could miss many potential modifiers, with subtle impairments that occur only in specific conditions. Thus, combined risk screens might constitute a novel era in PD research, for which a simple functional model is needed.



**Figure 6. The potential for functional modelling PD GWAS loci in *C. elegans***

The most recent PD GWAS meta-analysis by Nalls et al [24] highlighted 90 genome-wide significant risk signals at 78 genomic regions, implicated in idiopathic PD. Search of the *C. elegans* orthologues of the nearest, or most relevant candidate genes suggested by the IPDGC GWAS locus browser [240], using Ortholist2 [29], demonstrated that 64 of the listed candidate risk genes have orthologues in *C. elegans*, yet to be characterised in the context of PD modelling.

As extensively detailed in this review, *C. elegans* orthologues of Mendelian PD genes such as *lrk-1* and *vps-35* show promising functional conservation with their human counterparts *LRRK2* and *VPS35*, when contrasted with a diverse range of *in vitro* and *in vivo* models. It is clear that in many model systems, *LRRK2* is a key player in PD pathway disruption and may further bridge the gap in our understanding of Mendelian to idiopathic PD. GWAS risk genes, such as *RAB29* (*glo-1* in *C. elegans*), also show great promise for further functional modelling in *C. elegans*. This opens the possibility of developing new nematode models to further understand the functionality of novel candidate genes, rapidly emerging through the availability of vast genetic data. The development of CRISPR/Cas9 technologies has enabled the rapid generation of knockin point mutations in *C. elegans* orthologues of human genes [56,258], although this approach is not yet as widely used as deletion, RNAi silencing and transgenic expression of PD-relevant genes [20,55,143,259,260]. Endogenous CRISPR/Cas9 engineered mutations enables precise modelling



of human genetic variants that might pose as risk for developing PD [261]. As *C. elegans* is one of the easiest and cheapest multicellular eukaryotic organism to apply precise genome editing to, the choice of this simple nematode for studying PD biology provides fast, cheap *in vivo* modelling with great translational potential [21,29,51], as discussed throughout this review. *C. elegans* functional studies of other Mendelian PD genes and their orthologues, including *PINK1*, *PARKIN*, *ATP13A2* and *DJ-1*, or PD risk genes, such as *GBA1*, have proven the strength of this invertebrate model, highlighting highly conserved functions of these genes and proteins in cellular pathways disrupted in PD, including mitophagy, lysosomal degradation and  $\alpha$ -synuclein pathology [49,132,175,262–270]. Complex functional interaction of all of these PD proteins and LRRK2 have been described in PD patient samples and in animal models, which supports the idea that LRRK2 is a master regulator of cellular trafficking and quality control pathways, maintaining a cross-talk of a multitude of cellular processes and reflects on the high complexity of Parkinson's disease pathology [13,271–274]. Developing oligogenic *C. elegans* models, replicating the human genetic changes and evaluating cross-talk of various cellular pathways in PD, will help in enabling the future development of novel, disease modifying therapeutics.

### Competing Interests

The authors declare that there are no competing interests associated with the manuscript.

### Funding

This research was funded by grants from Parkinson's UK [grant numbers H-1702 and G-2008]; the Medical Research Council [grant number MR/N026004/1]; Michael J Fox Foundation [grant number 18285]; Aligning Science Against Parkinson's consortium [grant number ASAP-0478]. R.J.C. is funded by Parkinson's UK PhD Studentship [grant number H-1702].

### Open Access

Open access for this article was enabled by the participation of University of Reading in an all-inclusive *Read & Publish* pilot with Portland Press and the Biochemical Society under a transformative agreement with JISC.

### Author Contribution

R.J.C. contributed to the manuscript preparation, writing, figures and background research, with additions from S.C. E.K., P.A.L. and S.C. contributed to the concept, background research, figures, editing and revisions of the manuscript. E.K., P.A.L., S.C. and R.J.C. all made intellectual contributions, edits and approvals to the manuscript for publication.

### Abbreviations

APP, amyloid precursor protein; ASO, antisense oligonucleotide; CME, clathrin-mediated endocytosis; PD, Parkinson's disease; PPI, protein-protein interaction.

### References

- 1 Trinh, J., Guella, I. and Farrer, M.J. (2014) Disease penetrance of late-onset parkinsonism: a meta-analysis. *JAMA Neurol.* **71**, 1535–1539, <https://doi.org/10.1001/jamaneurol.2014.1909>
- 2 Postuma, R.B., Berg, D., Stern, M., Poewe, W., Olanow, C.W., Oertel, W. et al. (2015) MDS clinical diagnostic criteria for Parkinson's disease. *Mov. Disord.* **30**, 1591–1601, <https://doi.org/10.1002/mds.26424>
- 3 Dickson, D.W., Braak, H., Duda, J.E., Duyckaerts, C., Gasser, T., Halliday, G.M. et al. (2009) Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. *Lancet Neurol.* **8**, 1150–1157, [https://doi.org/10.1016/S1474-4422\(09\)70238-8](https://doi.org/10.1016/S1474-4422(09)70238-8)
- 4 Ali, K. and Morris, H.R. (2015) Parkinson's disease: chameleons and mimics. *Pract. Neurol.* **15**, 14–25, <https://doi.org/10.1136/practneurol-2014-000849>
- 5 Schrag, A., Horsfall, L., Walters, K., Noyce, A. and Petersen, I. (2015) Prediagnostic presentations of Parkinson's disease in primary care: A case-control study. *Lancet Neurol.* **14**, 57–64, [https://doi.org/10.1016/S1474-4422\(14\)70287-X](https://doi.org/10.1016/S1474-4422(14)70287-X)
- 6 Muller, T., Kuhn, W. and Przuntek, H. (1997) Non-motor symptoms of Parkinson disease. Significant impact on quality of life—using possible treatments. *Fortschr. Med.* **115**, 45–48
- 7 Wu, Y.H., Lee, W.J., Chen, Y.H., Chang, M.H. and Lin, C.H. (2016) Premotor symptoms as predictors of outcome in Parkinson's disease: a case-control study. *PLoS ONE* **17**, 11, <https://doi.org/10.1371/journal.pone.0161271>
- 8 Wider, C., Skipper, L., Solida, A., Brown, L., Farrer, M., Dickson, D. et al. (2008) Autosomal dominant dopa-responsive parkinsonism in a multigenerational Swiss family. *Park Relat. Disord.* **14**, 465–470, <https://doi.org/10.1016/j.parkrel.2007.11.013>
- 9 Braak, H., Del, K., Rüb, U., de Vos, R.A.L., Jansen, E.N.H. and Braak, E. (2003) Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiol. Aging* **24**, 197–211, [https://doi.org/10.1016/S0197-4580\(02\)00065-9](https://doi.org/10.1016/S0197-4580(02)00065-9)
- 10 Marder, K., Wang, Y., Alcalay, R.N., Mejia-Santana, H., Tang, M.X., Lee, A. et al. (2015) Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium. *Neurology* **85**, 89–95, <https://doi.org/10.1212/WNL.0000000000001708>

- 11 Braak, H., Rüb, U., Gai, W.P. and Del Tredici, K. (2003) Idiopathic Parkinson's disease: Possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. *J. Neural Transm.* **110**, 517–536, <https://doi.org/10.1007/s00702-002-0808-2>
- 12 Ma, C., Liu, Y., Neumann, S. and Gao, X. (2017) Nicotine from cigarette smoking and diet and Parkinson's disease: a review. *Transl. Neurodegener.* **6**, 1–7, <https://doi.org/10.1186/s40035-017-0090-8>
- 13 Hernandez, D.G., Reed, X. and Singleton, A.B. (2016) Genetics in Parkinson's disease: Mendelian versus non-Mendelian inheritance. *J. Neurochem.* **139**, 59–74, <https://doi.org/10.1111/jnc.13593>
- 14 Struhal, W., Presslauer, S., Spielberger, S., Zimprich, A., Auff, E., Bruecke, T. et al. (2014) VPS35 Parkinson's disease phenotype resembles the sporadic disease. *J. Neural. Transm.* **121**, 755–759, <https://doi.org/10.1007/s00702-014-1179-1>
- 15 Li, Y., Ikeda, A., Yoshino, H., Oyama, G., Kitani, M., Daida, K. et al. (2020) Clinical characterization of patients with leucine-rich repeat kinase 2 genetic variants in Japan. *J. Hum. Genet.* **65**, 771–781, <https://doi.org/10.1038/s10038-020-0772-4>
- 16 Bandres-Ciga, S., Saez-Atienzar, S., Bonet-Ponce, L., Billingsley, K., Vitale, D., Blauwendraat, C. et al. (2019) The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease. *Mov. Disord.* 1–9, <https://doi.org/10.1002/mds.27614>
- 17 Robak, L.A., Jansen, I.E., van Rooij, J., Uitterlinden, A.G., Kraaij, R., Jankovic, J. et al. (2017) Excessive burden of lysosomal storage disorder gene variants in Parkinson's disease. *Brain* **140**, 3191–3203, <https://doi.org/10.1093/brain/awx285>
- 18 Lubbe, S.J., Escott-Price, V., Gibbs, J.R., Nalls, M.A., Bras, J., Price, T.R. et al. (2016) Additional rare variant analysis in Parkinson's disease cases with and without known pathogenic mutations: evidence for oligogenic inheritance. *Assoc. Stud. Artic* **25**, 5483–5489, <https://doi.org/10.1093/hmg/ddw348>
- 19 Keogh, M.J., Wei, W., Aryaman, J., Wilson, I., Talbot, K., Turner, M.R. et al. (2018) Oligogenic genetic variation of neurodegenerative disease genes in 980 postmortem human brains. *J. Neurol. Neurosurg. Psychiatry* **89**, 813–816, <https://doi.org/10.1136/jnnp-2017-317234>
- 20 Caldwell, K.A., Willcott, C.W. and Caldwell, G.A. (2020) Modeling neurodegeneration in *Caenorhabditis elegans*. *Dis. Model Mech.* **13**, 1–15, <https://doi.org/10.1242/dmm.046110>
- 21 Cooper, J.F. and Van Raamsdonk, J.M. (2018) Modeling Parkinson's disease in *C. elegans*. *J. Parkinsons Dis.* **8**, 17–32, <https://doi.org/10.3233/JPD-171258>
- 22 Blauwendraat, C., Nalls, M.A. and Singleton, A.B. (2020) The genetic architecture of Parkinson's disease. *Lancet Neurol.* **19**, 170–178, [https://doi.org/10.1016/S1474-4422\(19\)30287-X](https://doi.org/10.1016/S1474-4422(19)30287-X)
- 23 Fung, H.C., Scholz, S., Matarin, M., Simon-Sanchez, S., Hernandez, D., Britton, A. et al. (2006) Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data. *Lancet Neurol.* **5**, 911–916, [https://doi.org/10.1016/S1474-4422\(06\)70578-6](https://doi.org/10.1016/S1474-4422(06)70578-6)
- 24 Nalls, M.A., Blauwendraat, C., Vallerga, C.L., Heilbron, K., Bandres-Ciga, S., Chang, D. et al. (2019) Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. *Lancet Neurol.* **18**, 1091–1102, [https://doi.org/10.1016/S1474-4422\(19\)30320-5](https://doi.org/10.1016/S1474-4422(19)30320-5)
- 25 Smolders, S. and Van Broeckhoven, C. (2020) Genetic perspective on the synergistic connection between vesicular transport, lysosomal and mitochondrial pathways associated with Parkinson's disease pathogenesis. *Acta Neuropathol. Commun.* **8**, 1–28, <https://doi.org/10.1186/s40478-020-00935-4>
- 26 Liu, Z.H., Guo, J.F., Li, K., Wang, Y.Q., Kang, J.F., Wei, Y. et al. (2015) Analysis of several loci from genome-wide association studies in Parkinson's disease in mainland China. *Neurosci. Lett.* **587**, 68–71, <https://doi.org/10.1016/j.neulet.2014.12.027>
- 27 Griffin, E.F., Caldwell, K.A. and Caldwell, G.A. (2017) Genetic and Pharmacological Discovery for Alzheimer's Disease Using *Caenorhabditis elegans*. *ACS Chem. Neurosci.* **8**, 2596–2606, <https://doi.org/10.1021/acschemneuro.7b00361>
- 28 Sandhof, C.A., Hoppe, S.O., Tittelmeier, J. and Nussbaum-Krammer, C. (2020) *C. Elegans* models to study the propagation of prions and prion-like proteins. *Biomolecules* **10**, 1–23, <https://doi.org/10.3390/biom10081188>
- 29 Kim, W., Underwood, R.S., Greenwald, I. and Shaye, D.D. (2018) Ortholist 2: A new comparative genomic analysis of human and *caenorhabditis elegans* genes. *Genetics* **210**, 445–461, <https://doi.org/10.1534/genetics.118.301307>
- 30 Bargmann, C.I. (1998) Neurobiology of the *Caenorhabditis elegans* genome. *Science (80-)* **282**, 2028–2033, <https://doi.org/10.1126/science.282.5396.2028>
- 31 Eneque, C.E.S., Iology, T.O.B. and The C. Consortium S. (1998) Genome sequence of the nematode *C. elegans*: A platform for investigating biology. *Science (80-)* **282**, 2012–2018, <https://doi.org/10.1126/science.282.5396.2012>
- 32 Walther, D.M., Kasturi, P., Zheng, M., Pinkert, S., Vecchi, G., Ciryam, P. et al. (2015) Widespread proteome remodeling and aggregation in aging *C. elegans*. *Cell* **161**, 919–932, <https://doi.org/10.1016/j.cell.2015.03.032>
- 33 Azulay, A., Itskovits, E. and Zaslaver, A. (2016) The *C. elegans* Connectome Consists of Homogenous Circuits with Defined Functional Roles. *PLoS Comput. Biol.* **12**, 1–16, <https://doi.org/10.1371/journal.pcbi.1005021>
- 34 Cook, S.J., Jarrell, T.A., Brittin, C.A., Wang, Y., Bloniarz, A.E., Yakovlev, M.A. et al. (2019) Whole-animal connectomes of both *Caenorhabditis elegans* sexes. *Nature* **571**, 63–71, <https://doi.org/10.1038/s41586-019-1352-7>
- 35 Maulik, M., Mitra, S., Bult-Ito, A., Taylor, B.E. and Vayndorf, E.M. (2017) Behavioral phenotyping and pathological indicators of Parkinson's disease in *C. elegans* models. *Front. Genet.* **8**, 1–21, <https://doi.org/10.3389/fgene.2017.00077>
- 36 Smith, L.L., Ryde, I.T., Hartman, J.H., Romersi, R.F., Markovich, Z. and Meyer, J.N. (2019) Strengths and limitations of morphological and behavioral analyses in detecting dopaminergic deficiency in *Caenorhabditis elegans*. *Neurotoxicology* **74**, 209–220, <https://doi.org/10.1016/j.neuro.2019.07.002>
- 37 Chase, D.L. and Koelle, M.R. (2007) Biogenic amine neurotransmitters in *C. elegans*. *WormBook* 1–15, <https://doi.org/10.1895/wormbook.1.132.1>
- 38 Ségalat, L., Elkes, D.A. and Kaplan, J.M. (1995) Modulation of serotonin-controlled behaviors by Go in *Caenorhabditis elegans*. *Science (80-)* **267**, 1648–1651, <https://doi.org/10.1126/science.7886454>

- 39 Ibáñez, P., Lesage, S., Lohmann, E., Thobois, S., De Michele, G., Borg, M. et al. (2006) Mutational analysis of the PINK1 gene in early-onset parkinsonism in Europe and North Africa. *Brain* **129**, 686–694, <https://doi.org/10.1093/brain/awl005>
- 40 Lesage, S., Lunati, A., Houot, M., Romdhan, S.B., Clot, F., Tesson, C. et al. (2020) Characterization of Recessive Parkinson Disease in a Large Multicenter Study. *Ann. Neurol.* **88**, 843–850, <https://doi.org/10.1002/ana.25787>
- 41 Pankratz, N., Pauculo, M.W., Elsaesser, V.E., Marek, D.K., Halter, C.A., Wojcieszek, J. et al. (2006) Mutations in DJ-1 are rare in familial Parkinson disease. *Neurosci. Lett.* **408**, 209–213, <https://doi.org/10.1016/j.neulet.2006.09.003>
- 42 Olgíati, S., Quadri, M., Fang, M., Rood, J.P.M.A., Saute, J.A., Chien, H.F. et al. (2016) DNAJC6 Mutations Associated with Early-Onset Parkinson's Disease. *Ann. Neurol.* **79**, 244–256, <https://doi.org/10.1002/ana.24553>
- 43 Vilariño-Güell, C., Rajput, A., Milnerwood, A.J., Shah, B., Szu-Tu, C., Trinh, J. et al. (2014) DNAJC13 mutations in Parkinson disease. *Hum. Mol. Genet.* **23**, 1794–1801, <https://doi.org/10.1093/hmg/ddt570>
- 44 Wilson, G.R., Sim, J.C.H., McLean, C., Giannandrea, M., Galea, C.A., Riseley, J.R. et al. (2014) Mutations in RAB39B cause X-linked intellectual disability and early-onset parkinson disease with  $\alpha$ -synuclein pathology. *Am. J. Hum. Genet.* **95**, 729–735, <https://doi.org/10.1016/j.ajhg.2014.10.015>
- 45 Di Fonzo, A., Chien, H.F., Socal, M., Giraudo, S., Tassorelli, C., Iliceto, G. et al. (2007) ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. *Neurology* **68**, 1557–1562, <https://doi.org/10.1212/01.wnl.0000260963.08711.08>
- 46 Puschmann, A. (2017) New Genes Causing Hereditary Parkinson's Disease or Parkinsonism. *Curr. Neurol. Neurosci. Rep.* **17**, 1–11, <https://doi.org/10.1007/s11910-017-0780-8>
- 47 Landrum, M.J. and Kattman, B.L. (2018) ClinVar at five years: Delivering on the promise. *Hum. Mutat.* **39**, 1623–1630, <https://doi.org/10.1002/humu.23641>
- 48 Sawin, E.R., Ranganathan, R. and Horvitz, H.R. (2000) *C. elegans* locomotory rate is modulated by the environment through a dopaminergic pathway and by experience through a serotonergic pathway. *Neuron* **26**, 619–631, [https://doi.org/10.1016/S0896-6273\(00\)81199-X](https://doi.org/10.1016/S0896-6273(00)81199-X)
- 49 Osuna-Luque, J., Rodríguez-Ramos, Á., del M Gámez-del-Estal, M. and Ruiz-Rubio, M. (2018) Behavioral Mechanisms That Depend on Dopamine and Serotonin in *Caenorhabditis elegans* Interact With the Antipsychotics Risperidone and Aripiprazole. *J. Exp. Neurosci.* **12**, 1–11, <https://doi.org/10.1177/1179069518798628>
- 50 Cooper, J.F., Dues, D.J., Spielbauer, K.K., Machiela, E., Senchuk, M.M. and Van Raamsdonk, J.M. (2015) Delaying aging is neuroprotective in Parkinson's disease: A genetic analysis in *C. Elegans* models. *Parkinsons Dis.* **1**, 15022, <https://doi.org/10.1038/npjparkd.2015.22>
- 51 Corsi, A.K., Wightman, B. and Chalfie, M. (2015) A transparent window into biology: A primer on *Caenorhabditis elegans*. *Genetics* **200**, 387–407, <https://doi.org/10.1895/wormbook.1.177.1>
- 52 Stein, L., Sternberg, P., Durbin, R., Thierry-Mieg, J. and Spieth, J. (2001) WormBase: Network access to the genome and biology of *Caenorhabditis elegans*. *Nucleic Acids Res.* **29**, 82–86, <https://doi.org/10.1093/nar/29.1.82>
- 53 Harris, T.W., Arnaboldi, V., Cain, S., Chan, J., Chen, W.J., Cho, J. et al. (2020) WormBase: a modern Model Organism Information Resource. *Nucleic Acids Res.* **48**, D762–D767
- 54 Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E. and Mello, C.C. (1998) Potent and specific genetic interference by double-stranded RNA in *Caenorhabditis elegans*. *Nature* **391**, 806–811, <https://doi.org/10.1038/35888>
- 55 Thompson, O., Edgley, M., Strasbourger, P., Flibotte, S., Ewing, B., Adair, R. et al. (2013) The million mutation project: A new approach to genetics in *Caenorhabditis elegans*. *Genome Res.* **23**, 1749–1762, <https://doi.org/10.1101/gr.157651.113>
- 56 Paix, A., Folkmann, A., Rasoloson, D. and Seydoux, G. (2015) High efficiency, homology-directed genome editing in *Caenorhabditis elegans* using CRISPR-Cas9 ribonucleoprotein complexes. *Genetics* **201**, 47–54
- 57 Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S. et al. (2004) Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology. *Neuron* **44**, 601–607, <https://doi.org/10.1016/j.neuron.2004.11.005>
- 58 Paisán-Ruiz, C., Jain, S., Evans, E.W., Gilks, W.P., Simón, J., Van Der Brug, M. et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. *Neuron* **44**, 595–600, <https://doi.org/10.1016/j.neuron.2004.10.023>
- 59 Ross, O.A., Soto-Ortolaza, A.I., Heckman, M.G., Aasly, J.O., Abahuni, N., Annesi, G. et al. (2011) Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: A case-control study. *Lancet Neurol.* **10**, 898–908, [https://doi.org/10.1016/S1474-4422\(11\)70175-2](https://doi.org/10.1016/S1474-4422(11)70175-2)
- 60 Tolosa, E., Vila, M., Klein, C. and Rascol, O. (2020) LRRK2 in Parkinson disease: challenges of clinical trials. *Nat. Rev. Neurol. Nat. Res* **16**, 97–107, <https://doi.org/10.1038/s41582-019-0301-2>
- 61 Di Maio, R., Hoffman, E.K., Rocha, E.M., Keeney, M.T., Sanders, L.H., De Miranda, B.R. et al. (2018) LRRK2 activation in idiopathic Parkinson's disease. *Sci. Transl. Med.* **10**, 1–13, <https://doi.org/10.1126/scitranslmed.aar5429>
- 62 Kluss, J.H., Mamais, A. and Cookson, M.R. (2019) LRRK2 links genetic and sporadic Parkinson's disease. *Biochem. Soc. Trans.* **47**, 651–661, <https://doi.org/10.1042/BST20180462>
- 63 Tolosa, E., Vila, M., Klein, C. and Rascol, O. (2020) LRRK2 in Parkinson disease: challenges of clinical trials. *Nat. Rev. Neurol.* **16**, 97–107, <https://doi.org/10.1038/s41582-019-0301-2>
- 64 Ren, J., Wen, L., Gao, X., Jin, C., Xue, Y. and Yao, X. (2009) DOG 1.0: Illustrator of protein domain structures. *Cell Res. Nat. Pub. roup* **19**, 271–273, Available from: [www.cell-research.com](http://www.cell-research.com), <https://doi.org/10.1038/cr.2009.6>
- 65 Rice, P., Longden, L. and Bleasby, A. (2000) EMBOSS: The European Molecular Biology Open Software Suite. *Trends Genet. Elsevier Ltd* **16**, 276–277, Available from: <http://www.cell.com/article/S0168952500020242/fulltext>, [https://doi.org/10.1016/S0168-9525\(00\)02024-2](https://doi.org/10.1016/S0168-9525(00)02024-2)
- 66 Waterman, M.S. and Eggert, M. (1987) A new algorithm for best subsequence alignments with application to tRNA-rRNA comparisons. *J. Mol. Biol.* **197**, 723–728, [https://doi.org/10.1016/0022-2836\(87\)90478-5](https://doi.org/10.1016/0022-2836(87)90478-5)
- 67 Needleman, S.B. and Wunsch, C.D. (1970) A general method applicable to the search for similarities in the amino acid sequence of two proteins. *J. Mol. Biol.* **48**, 443–453, [https://doi.org/10.1016/0022-2836\(70\)90057-4](https://doi.org/10.1016/0022-2836(70)90057-4)

- 68 Wauters, L., Versées, W. and Korholt, A. (2019) Roco Proteins: GTPases with a Baroque Structure and Mechanism. *Int. J. Mol. Sci.* **20**, 147, <https://doi.org/10.3390/ijms20010147>
- 69 Sejwal, K., Chami, M., Rémy, H., Vancraenenbroeck, R., Sibran, W., Sütterlin, R. et al. (2017) Cryo-EM analysis of homodimeric full-length LRRK2 and LRRK1 protein complexes. *Sci. Rep.* **7**, 1–12, <https://doi.org/10.1038/s41598-017-09126-z>
- 70 Guaitoli, G., Raimondi, F., Gilsbach, B.K., Gómez-Llorente, Y., Deyaert, E., Renzi, F. et al. (2016) Structural model of the dimeric Parkinson's protein LRRK2 reveals a compact architecture involving distant interdomain contacts. *Proc. Natl. Acad. Sci.* **113**, E4357–E4466, <https://doi.org/10.1073/pnas.1523708113>
- 71 Gloeckner, C.J. and Porras, P. (2020) Guilt-by-Association - Functional Insights Gained From Studying the LRRK2 Interactome. *Front. Neurosci.* **14**, 1–14, <https://doi.org/10.3389/fnins.2020.00485>
- 72 Greggio, E., Jain, S., Kingsbury, A., Bandopadhyay, R., Lewis, P., Kaganovich, A. et al. (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. *Neurobiol. Dis.* **23**, 329–341, <https://doi.org/10.1016/j.nbd.2006.04.001>
- 73 Smith, W.W., Pei, Z., Jiang, H., Dawson, V.L., Dawson, T.M. and Ross, C.A. (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity. *Nat. Neurosci.* **9**, 1231–1233, <https://doi.org/10.1038/nn1776>
- 74 Taymans, J.M., Vancraenenbroeck, R., Ollikainen, P., Beilina, A., Lobbstaël, E., de Maeyer, M. et al. (2011) LRRK2 kinase activity is dependent on LRRK2 gtp binding capacity but independent of LRRK2 GTP binding. *PLoS One* **6**, <https://doi.org/10.1371/journal.pone.0023207>
- 75 West, A.B., Moore, D.J., Choi, C., Andrabi, S.A., Li, X., Dikeman, D. et al. (2007) Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. *Hum. Mol. Genet.* **16**, 223–232, <https://doi.org/10.1093/hmg/ddl471>
- 76 Yao, C., El Khoury, R., Wang, W., Byrd, T.A., Pehek, E.A., Thacker, C. et al. (2010) LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease. *Neurobiol. Dis.* **40**, 73–81, <https://doi.org/10.1016/j.nbd.2010.04.002>
- 77 West, A.B., Moore, D.J., Biskup, S., Bugayenko, A., Smith, W.W., Ross, C.A. et al. (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. *Proc. Natl. Acad. Sci. U.S.A.* **102**, 16842–16847, <https://doi.org/10.1073/pnas.0507360102>
- 78 Berwick, D.C., Javaheri, B., Wetzel, A., Hopkinson, M., Nixon-Abell, J., Grannò, S. et al. (2017) Pathogenic LRRK2 variants are gain-of-function mutations that enhance LRRK2-mediated repression of  $\beta$ -catenin signaling. *Mol. Neurodegener.* **12**, 29–39, <https://doi.org/10.1186/s13024-017-0153-4>
- 79 Study to Evaluate DNL201 in Subjects With Parkinson's Disease - Full Text View - ClinicalTrials.gov. Available from: <https://clinicaltrials.gov/ct2/show/NCT03710707>
- 80 Study to Evaluate DNL151 in Subjects With Parkinson's Disease - Full Text View - ClinicalTrials.gov. Available from: <https://clinicaltrials.gov/ct2/show/NCT04056689>
- 81 Lewis, P.A., Greggio, E., Beilina, A., Jain, S., Baker, A. and Cookson, M.R. (2007) The R1441C mutation of LRRK2 disrupts GTP hydrolysis. *Biochem. Biophys. Res. Commun.* **357**, 668–671, <https://doi.org/10.1016/j.bbrc.2007.04.006>
- 82 Li, X., Tan, Y.C., Poulouse, S., Olanow, C.W., Huang, X.Y. and Yue, Z. (2007) Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. *J. Neurochem.* **103**, 238–247
- 83 Li, Y., Dunn, L., Greggio, E., Krumm, B., Jackson, G.S., Cookson, M.R. et al. (2009) The R1441C mutation alters the folding properties of the ROC domain of LRRK2. *Biochim. Biophys. Acta - Mol. Basis Dis.* **1792**, 1194–1197, <https://doi.org/10.1016/j.bbdis.2009.09.010>
- 84 Huang, X., Wu, C., Park, Y., Long, X., Hoang, Q.Q. and Liao, J. (2018) The Parkinson's disease-associated mutation N1437H impairs conformational dynamics in the G domain of LRRK2. *FASEB J.* **33**, 4814–4823
- 85 Hovemann, B., Ziegler, A.B., Trifunovic, A., Nolte, H., Krüger, M., Moore, D.J. et al. (2016) Human R1441C LRRK2 regulates the synaptic vesicle proteome and phosphoproteome in a Drosophila model of Parkinson's disease. *Hum. Mol. Genet.* **25**
- 86 Nguyen, A.P.T., Tsika, E., Kelly, K., Levine, N., Chen, X., West, A.B. et al. (2020) Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity. *Proc. Natl. Acad. Sci. U.S.A.* **117**, 17296–17307
- 87 Chen, M.L. and Wu, R.M. (2018) LRRK 2 gene mutations in the pathophysiology of the ROCO domain and therapeutic targets for Parkinson's disease: A review Julie Y.H. Chan. *J. Biomed. Sci.* **25**, 1–11
- 88 Gloeckner, C.J., Kinkl, N., Schumacher, A., Braun, R.J., O'Neill, E., Meitinger, T. et al. (2006) The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. *Hum. Mol. Genet.* **15**, 223–232, <https://doi.org/10.1093/hmg/ddi439>
- 89 Liu, Z., Bryant, N., Kumaran, R., Beilina, A., Abeliovich, A., Cookson, M.R. et al. (2018) LRRK2 phosphorylates membrane-bound Rabs and is activated by GTP-bound Rab7L1 to promote recruitment to the trans-Golgi network. *Hum. Mol. Genet.* **27**, 385–395, <https://doi.org/10.1093/hmg/ddx410>
- 90 Tsika, E. and Moore, D.J. (2013) Contribution of GTPase activity to LRRK2-associated Parkinson disease. *Small GTPases* **4**, 164–70
- 91 Bios, A., Trancikova, A., Civiero, L., Glauser, L., Bubacco, L., Greggio, E. et al. (2013) GTPase activity regulates kinase activity and cellular phenotypes of parkinson's disease-associated LRRK2. *Hum. Mol. Genet.* **22**, 1140–1156, <https://doi.org/10.1093/hmg/dd522>
- 92 Ramírez, M.B., Ordóñez, A.J.L., Fdez, E., Madero-Pérez, J., Gonnelli, A., Drouyer, M. et al. (2017) GTP binding regulates cellular localization of Parkinson's disease-associated LRRK2. *Hum. Mol. Genet.* **26**, 2747–2767, <https://doi.org/10.1093/hmg/ddx161>
- 93 Civiero, L., Vancraenenbroeck, R., Belluzzi, E., Beilina, A., Lobbstaël, E., Reyniers, L. et al. (2012) Biochemical Characterization of Highly Purified Leucine-Rich Repeat Kinases 1 and 2 Demonstrates Formation of Homodimers. *PLoS One* **7**, e43472, <https://doi.org/10.1371/journal.pone.0043472>
- 94 Greggio, E., Zambrano, I., Kaganovich, A., Beilina, A., Taymans, J.M., Daniëls, V. et al. (2008) The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. *J. Biol. Chem.* **283**, 16906–16914, <https://doi.org/10.1074/jbc.M708718200>
- 95 Deyaert, E., Wauters, L., Guaitoli, G., Konijnenberg, A., Leemans, M., Terheyden, S. et al. (2017) A homologue of the Parkinson's disease-associated protein LRRK2 undergoes a monomer-dimer transition during GTP turnover. *Nat. Commun.* **8**, 1–12, <https://doi.org/10.1038/s41467-017-01103-4>

- 96 Berwick, D.C., Heaton, G.R., Azeggagh, S. and Harvey, K. (2019) LRRK2 Biology from structure to dysfunction: research progresses, but the themes remain the same. *Mol. Neurodegeneration* **14**, 49, <https://doi.org/10.1186/s13024-019-0344-2>
- 97 Steger, M., Tonelli, F., Ito, G., Davies, P., Trost, M., Vetter, M. et al. (2016) Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases. *Elife* **29**, 5, <https://doi.org/10.7554/eLife.12813>
- 98 Sheng, Z., Zhang, S., Bustos, D., Kleinheinz, T., Le Pichon, C.E., Dominguez, S.L. et al. (2012) Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. *Sci. Transl. Med.* **4**, 164ra161, <https://doi.org/10.1126/scitranslmed.3004485>
- 99 Mir, R., Tonelli, F., Lis, P., Macartney, T., Polinski, N.K., Martinez, T.N. et al. (2018) The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human. *Biochem. J.* **475**, 1861–1883, <https://doi.org/10.1042/BCJ20180248>
- 100 Takanashi, M., Funayama, M., Matsuura, E., Yoshino, H., Li, Y., Tsuyama, S. et al. (2018) Isolated nigral degeneration without pathological protein aggregation in autopsied brains with LRRK2 p.R1441H homozygous and heterozygous mutations. *Acta Neuropathol. Commun.* **6**, 105, <https://doi.org/10.1186/s40478-018-0617-y>
- 101 Guerreiro, P.S., Gerhardt, E., Lopes da Fonseca, T., Bähr, M., Outeiro, T.F. and Eckermann, K. (2016) LRRK2 Promotes Tau Accumulation, Aggregation and Release. *Mol. Neurobiol.* **53**, 3124–3135, <https://doi.org/10.1007/s12035-015-9209-z>
- 102 Henderson, M.X., Sengupta, M., Trojanowski, J.Q. and Lee, V.M.Y. (2019) Alzheimer's disease tau is a prominent pathology in LRRK2 Parkinson's disease. *Acta Neuropathol Commun.* **7**, 183, <https://doi.org/10.1186/s40478-019-0836-x>
- 103 Rhodes, S.L., Sinsheimer, J.S., Bordelon, Y., Bronstein, J.M. and Ritz, B. (2010) Replication of GWAS Associations for GAK and MAPT in Parkinson's Disease. *Ann. Hum. Genet.* **75**, 195–200, <https://doi.org/10.1111/j.1469-1809.2010.00616.x>
- 104 Smith, C., Malek, N., Grosset, K., Cullen, B., Gentleman, S. and Grosset, D.G. (2019) Neuropathology of dementia in patients with Parkinson's disease: A systematic review of autopsy studies. *J. Neurol. Neurosurg. Psychiatry. BMJ Publishing Group* **90**, 1234–1243, <https://doi.org/10.1136/jnnp-2019-321111>
- 105 Kim, W.S., Kagedal, K. and Halliday, G.M. (2014) Alpha-synuclein biology in Lewy body diseases. *Alzheimer's Res Ther.* **6**, 1–9, <https://doi.org/10.1186/s13195-014-0073-2>
- 106 Zhang, X., Gao, F., Wang, D., Li, C., Fu, Y., He, W. et al. (2018) Tau pathology in Parkinson's disease. *Front Neurol.* **9**, 1–7, <https://doi.org/10.3389/fneur.2018.00809>
- 107 Guerreiro, R., Escott-Price, V., Darwent, L., Parkkinen, L., Ansorge, O., Hernandez, D.G. et al. (2016) Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. *Neurobiol. Aging* **38**, 214, <https://doi.org/10.1016/j.neurobiolaging.2015.10.028>
- 108 Prusiner, S.B., Woerman, A.L., Mordes, D.A., Watts, J.C., Rampersauda, R., Berry, D.B. et al. (2015) Evidence for  $\alpha$ -synuclein prions causing multiple system atrophy in humans with parkinsonism. *Proc. Natl Acad. Sci.* **79**, 5308–5317, <https://doi.org/10.1073/pnas.1514475112>
- 109 Lippa, C.F., Fujiwara, H., Mann, D.M.A., Giasson, B., Baba, M., Schmidt, M.L. et al. (1998) Lewy bodies contain altered  $\alpha$ -synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. *Am. J. Pathol.* **153**, 1365–1370, [https://doi.org/10.1016/S0002-9440\(10\)65722-7](https://doi.org/10.1016/S0002-9440(10)65722-7)
- 110 Bateman, R.J., Xiong, C., Benzinger, T.L.S., Fagan, A.M., Goate, A., Fox, N.C. et al. (2012) Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease. *N. Engl. J. Med.* **367**, 795–804, <https://doi.org/10.1056/NEJMoa1202753>
- 111 Boxer, A.L., Yu, J.T., Golbe, L.I., Litvan, I., Lang, A.E. and Höglinger, G.U. (2017) Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. *Lancet Neurol.* **16**, 552–563, [https://doi.org/10.1016/S1474-4422\(17\)30157-6](https://doi.org/10.1016/S1474-4422(17)30157-6)
- 112 Kara, E., Ling, H., Pittman, A.M., Shaw, K., de Silva, R., Simone, R. et al. (2012) The MAPT p.A152T variant is a risk factor associated with tauopathies with atypical clinical and neuropathological features. *Neurobiol. Aging* **33**, 2231, <https://doi.org/10.1016/j.neurobiolaging.2012.04.006>
- 113 Lewis, P.A. (2019) Leucine rich repeat kinase 2: a paradigm for pleiotropy. *J. Physiol.* **597**, 3511–3521, <https://doi.org/10.1113/JP276163>
- 114 Jabbari, E., Koga, S., Valentino, R.R., Reynolds, R.H., Ferrari, R., Tan, M.M.X. et al. (2021) Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study. *Lancet Neurol.* **20**, 107–116
- 115 Hakimi, M., Selvanantham, T., Swinton, E., Padmore, R.F., Tong, Y., Kabbach, G. et al. (2011) Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. *J. Neural Transm.* **118**, 795–808, <https://doi.org/10.1007/s00702-011-0653-2>
- 116 Cook, D.A., Kannarkat, G.T., Cintron, A.F., Butkovich, L.M., Fraser, K.B., Chang, J. et al. (2017) LRRK2 levels in immune cells are increased in Parkinson's disease. *NPJ Park Dis.* **3**, 11, <https://doi.org/10.1038/s41531-017-0010-8>
- 117 Zhang, F.-R., Huang, W., Chen, S.-M., Sun, L.-D., Liu, H., Li, Y. et al. (2009) Genomewide Association Study of Leprosy. *N. Engl. J. Med.* **361**, 2609–2618, <https://doi.org/10.1056/NEJMoa0903753>
- 118 Hui, K.Y., Fernandez-Hernandez, H., Hu, J., Schaffner, A., Pankratz, N., Hsu, N.Y. et al. (2018) Functional variants in the LRRK2 gene confer shared effects on risk for Crohn's disease and Parkinson's disease. *Sci. Transl. Med.* **10**, 7795, <https://doi.org/10.1126/scitranslmed.aai7795>
- 119 A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIB094 in Adults With Parkinson's Disease - Full Text View - ClinicalTrials.gov. Available from: <https://www.clinicaltrials.gov/ct2/show/NCT03976349>
- 120 Chen, I. (2019) An antisense oligonucleotide splicing modulator to treat spinal muscular atrophy. *Nat. Res.* **2020**, 490–507
- 121 Lewis, P.A. (2009) The function of ROCO proteins in health and disease. *Biol. Cell.* **101**, 183–191, <https://doi.org/10.1042/BC20080053>
- 122 Rideout, H.J., Chartier-Harlin, M.C., Fell, M.J., Hirst, W.D., Huntwork-Rodriguez, S., Leyns, C.E.G. et al. (2020) The Current State-of-the Art of LRRK2-Based Biomarker Assay Development in Parkinson's Disease. *Front. Neurosci. Front. Media S.A.* **14**, 865
- 123 Kelly, K. and West, A.B. (2020) Pharmacodynamic Biomarkers for Emerging LRRK2 Therapeutics. *Front. Neurosci. Front. Media S.A.* **14**, 807
- 124 Lee, B.D., Shin, J.H., Vankampen, J., Petrucelli, L., West, A.B., Ko, H.S. et al. (2010) Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. *Nat. Med.* **16**, 998–1000, <https://doi.org/10.1038/nm.2199>
- 125 Daher, J.P.L., Volpicelli-Daley, L.A., Blackburn, J.P., Moehle, M.S. and West, A.B. (2014) Abrogation of  $\alpha$ -synuclein -mediated dopaminergic neurodegeneration in LRRK2-deficient rats. *Proc. Natl. Acad. Sci. U. S. A.* **111**, 9289–9294, <https://doi.org/10.1073/pnas.1403215111>

- 126 Daher, J.P.L., Abdelmotilib, H.A., Hu, X., Volpicelli-Daley, L.A., Moehle, M.S., Fraser, K.B. et al. (2015) Leucine-rich repeat kinase 2 (LRRK2) pharmacological inhibition abates  $\alpha$ -synuclein gene-induced neurodegeneration. *J. Biol. Chem.* **290**, 19433–19444, <https://doi.org/10.1074/jbc.M115.660001>
- 127 Korecka, J.A., Thomas, R., Hinrich, A.J., Moskites, A.M., Macbain, Z.K., Hallett, P.J. et al. (2020) Splice-Switching Antisense Oligonucleotides Reduce LRRK2 Kinase Activity in Human LRRK2 Transgenic Mice. *Mol. Ther. - Nucleic Acids* **21**, 623–635, <https://doi.org/10.1016/j.omtn.2020.06.027>
- 128 Zhao, H.T., John, N., Delic, V., Ikeda-Lee, K., Kim, A., Weihofen, A. et al. (2017) LRRK2 Antisense Oligonucleotides Ameliorate  $\alpha$ -Synuclein Inclusion Formation in a Parkinson's Disease Mouse Model. *Mol. Ther. - Nucleic Acids* **8**, 508–519, <https://doi.org/10.1016/j.omtn.2017.08.002>
- 129 Marín, I. (2006) The Parkinson disease gene LRRK2: Evolutionary and structural insights. *Mol. Biol. Evol.* **23**, 2423–2433, <https://doi.org/10.1093/molbev/msl114>
- 130 Marín, I. (2008) Ancient origin of the parkinson disease gene LRRK2. *J. Mol. Evol.* **67**, 41–50, <https://doi.org/10.1007/s00239-008-9122-4>
- 131 Force, A., Lynch, M., Pickett, F.B., Amores, A., Yan, Y. and Postlethwait, J. (1999) Preservation of Duplicate Genes by Complementary, Degenerative Mutations. *Genetics* **151**, 1531–1545
- 132 Sámán, J., Hegemann, J., von Gromoff, E., Eimer, S., Baumeister, R. and Schmidt, E. (2009) *Caenorhabditis elegans* LRK-1 and PINK-1 act antagonistically in stress response and neurite outgrowth. *J. Biol. Chem.* **284**, 16482–16491
- 133 Sakaguchi-Nakashima, A., Meir, J.Y., Jin, Y., Matsumoto, K. and Hisamoto, N. (2007) LRK-1, a *C. elegans* PARK8-Related Kinase, Regulates Axonal-Dendritic Polarity of SV Proteins. *Curr. Biol.* **17**, 592–598, <https://doi.org/10.1016/j.cub.2007.01.074>
- 134 Reyniers, L., Del Giudice, M.G., Civiero, L., Belluzzi, E., Lobbstaël, E., Beilina, A. et al. (2014) Differential protein protein interactions of LRRK1 and LRRK2 indicate roles in distinct cellular signaling pathways. *J. Neurochem.* **131**, 239–250, <https://doi.org/10.1111/jnc.12798>
- 135 Tomkins, J.E., Dihanich, S., Beilina, A., Ferrari, R., Ilacqua, N., Cookson, M.R. et al. (2018) Comparative Protein Interaction Network Analysis Identifies Shared and Distinct Functions for the Human ROCO Proteins. *Proteomics* **18**, 1–12
- 136 EMBOSS Stretcher < Pairwise Sequence Alignment < EMBL-EBI. Available from: [https://www.ebi.ac.uk/Tools/psa/emboss\\_stretcher/](https://www.ebi.ac.uk/Tools/psa/emboss_stretcher/)
- 137 Malik, A.U., Karapetsas, A., Nirujogi, R.S., Mathea, S., Chatterjee, D., Pal, P. et al. (2021) Deciphering the LRRK code: LRRK1 and LRRK2 phosphorylate distinct Rab proteins and are regulated by diverse mechanisms. *Biochem. J.* **478**, 553–578
- 138 Iida, A., Xing, W., Docx, M.K.F., Nakashima, T., Wang, Z., Kimizuka, M. et al. (2016) Identification of biallelic LRRK1 mutations in osteosclerotic metaphyseal dysplasia and evidence for locus heterogeneity. *J. Med. Genet.* **53**, 568–574
- 139 Miryounesi, M., Nikfar, A., Changi-Ashtiani, M., Shahrooei, M., Dinmohammadi, H., Shahani, T. et al. (2020) A novel homozygous LRRK1 stop gain mutation in a patient suspected with osteosclerotic metaphyseal dysplasia. *Ann. Hum. Genet.* **84**, 102–106, <https://doi.org/10.1111/ahg.12352>
- 140 Howaldt, A., Hennig, A.F., Rolvien, T., Rössler, U., Stelzer, N., Knaus, A. et al. (2020) Adult Osteosclerotic Metaphyseal Dysplasia With Progressive Osteonecrosis of the Jaws and Abnormal Bone Resorption Pattern Due to a LRRK1 Splice Site Mutation. *J. Bone Miner. Res.* **35**, 1322–1332, <https://doi.org/10.1002/jbmr.3995>
- 141 Yao, C., El Khoury, R., Wang, W., Byrd, T.A., Pehek, E.A., Thacker, C. et al. (2010) LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a *Caenorhabditis elegans* model of Parkinson's disease. *Neurobiol. Dis.* **40**, 73–81, <https://doi.org/10.1016/j.nbd.2010.04.002>
- 142 Luth, E.S., Stavrovskaya, I.G., Bartels, T., Kristal, B.S. and Selkoe, D.J. (2014) LRRK2 modulates vulnerability to mitochondrial dysfunction in *C. elegans*. *J. Biol. Chem.* **289**, 21490–21507
- 143 Kamath, R.S., Fraser, A.G., Dong, Y., Poulin, G., Durbin, R., Gotta, M. et al. (2003) Systematic functional analysis of the *Caenorhabditis elegans* genome using RNAi. *Nature* **421**, 231–237, <https://doi.org/10.1038/nature01278>
- 144 Blauwendraat, C., Reed, X., Kia, D.A., Gan-Or, Z., Lesage, S., Pihlström, L. et al. (2018) Frequency of loss of function variants in LRRK2 in Parkinson disease. *JAMA Neurol.* **75**, 1416–1422, <https://doi.org/10.1001/jamaneurol.2018.1885>
- 145 Whiffin, N., Armean, I.M., Kleinman, A., Marshall, J.L., Minikel, E.V., Goodrich, J.K. et al. (2020) The effect of LRRK2 loss-of-function variants in humans. *Nat. Med.* **26**, 869–877, <https://doi.org/10.1038/s41591-020-0893-5>
- 146 Fuji, R.N., Flagella, M., Baca, M., Baptista, M.A.S., Brodbeck, J., Chan, B.K. et al. (2015) Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. *Sci. Transl. Med.* **7**, 273, <https://doi.org/10.1126/scitranslmed.aaa3634>
- 147 Reyniers, L., Del Giudice, M.G., Civiero, L., Belluzzi, E., Lobbstaël, E., Beilina, A. et al. (2014) Differential protein protein interactions of LRRK1 and LRRK2 indicate roles in distinct cellular signaling pathways. *J. Neurochem.* **131**, 239–250, <https://doi.org/10.1111/jnc.12798>
- 148 Saha, S., Guillily, M.D., Ferree, A., Lanceta, J., Chan, D., Ghosh, J. et al. (2009) LRRK2 modulates vulnerability to mitochondrial dysfunction in *Caenorhabditis elegans*. *J. Neurosci.* **29**, 9210–9218, <https://doi.org/10.1523/JNEUROSCI.2281-09.2009>
- 149 Schaffner, A., Li, X., Gomez-Llorente, Y., Leandrou, E., Memou, A., Clemente, N. et al. (2019) Vitamin B 12 modulates Parkinson's disease LRRK2 kinase activity through allosteric regulation and confers neuroprotection. *Cell Res.* **29**, 313–329
- 150 Langston, R.G., Rudenko, I.N., Kumaran, R., Hauser, D.N., Kaganovich, A., Ponce, L.B. et al. (2019) Differences in Stability, Activity and Mutation Effects Between Human and Mouse Leucine-Rich Repeat Kinase 2. *Neurochem. Res.* **44**, 1446–1459, <https://doi.org/10.1007/s11064-018-2650-4>
- 151 Bieri, G., Brahic, M., Bousset, L., Couthouis, J., Kramer, N.J., Ma, R. et al. (2019) LRRK2 modifies  $\alpha$ -syn pathology and spread in mouse models and human neurons. *Acta Neuropathol.* **137**, 961–980, <https://doi.org/10.1007/s00401-019-01995-0>
- 152 Nguyen, A.P.T., Daniel, G., Valdés, P., Islam, M.S., Schneider, B.L. and Moore, D.J. (2018) G2019S LRRK2 enhances the neuronal transmission of tau in the mouse brain. *Hum. Mol. Genet.* **27**, 120–134, <https://doi.org/10.1093/hmg/ddx389>
- 153 Kim, H., Perentis, R.J., Caldwell, G.A. and Caldwell, K.A. (2018) Gene-by-environment interactions that disrupt mitochondrial homeostasis cause neurodegeneration in *C. elegans* Parkinson's models. *Cell Death Dis.* **9**, 1–15, <https://doi.org/10.1038/s41419-018-0619-5>
- 154 Smith, L.L., Ryde, I.T., Hartman, J.H., Romers, R.F., Markovich, Z. and Meyer, J.N. (2019) Strengths and limitations of morphological and behavioral analyses in detecting dopaminergic deficiency in *Caenorhabditis elegans*. *Neurotoxicology* **74**, 209–220, <https://doi.org/10.1016/j.neuro.2019.07.002>

- 155 Ray, A., Martinez, B.A., Berkowitz, L.A., Caldwell, G.A. and Caldwell, K.A. (2014) Mitochondrial dysfunction, oxidative stress, and neurodegeneration elicited by a bacterial metabolite in a *C. elegans* Parkinson's model. *Cell Death Dis.* **5**, 984–1012, <https://doi.org/10.1038/cddis.2013.513>
- 156 Wolozin, B., Saha, S., Guillily, M., Ferree, A. and Riley, M. (2008) Investigating convergent actions of genes linked to familial Parkinson's disease. *Neurodegener Dis.* **5**, 182–185, <https://doi.org/10.1159/000113697>
- 157 Deng, X., Dzamko, N., Prescott, A., Davies, P., Liu, Q., Yang, Q. et al. (2011) Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. *Nat. Chem. Biol.* **7**, 203–205, <https://doi.org/10.1038/nchembio.538>
- 158 Yao, C., Johnson, W.M., Gao, Y., Wang, W., Zhang, J., Deak, M. et al. (2013) Kinase inhibitors arrest neurodegeneration in cell and *C. elegans* models of LRRK2 toxicity. *Hum. Mol. Genet.* **22**, 328–344, <https://doi.org/10.1093/hmg/ddt431>
- 159 MacLeod, D.A., Rhinn, H., Kuwahara, T., Zolin, A., Di Paolo, G., MacCabe, B.D. et al. (2013) RAB7L1 Interacts with LRRK2 to Modify Intraneuronal Protein Sorting and Parkinson's Disease Risk. *Neuron* **77**, 425–439
- 160 Choudhary, B., Kamak, M., Ratnakaran, N., Kumar, J., Awasthi, A., Li, C. et al. (2017) UNC-16/JIP3 regulates early events in synaptic vesicle protein trafficking via LRK-1/LRRK2 and AP complexes. *PLoS Genet* **13**, e1007100
- 161 Boecker, C.A., Goldsmith, J., Dou, D., Cajka, G.G. and Holzbaur, E.L.F. (2021) Increased LRRK2 kinase activity alters neuronal autophagy by disrupting the axonal transport of autophagosomes. *Curr. Biol.* **31**, 2140–2154
- 162 Heaton, G.R., Landeck, N., Mamais, A., Nalls, M.A., Nixon-Abell, J., Kumaran, R. et al. (2020) Sequential screening nominates the Parkinson's disease associated kinase LRRK2 as a regulator of Clathrin-mediated endocytosis. *Neurobiol. Dis.* **141**, 104948
- 163 Vidyadhara, D.J., Lee, J.E. and Chandra, S.S. (2019) Role of the endolysosomal system in Parkinson's disease. *J. Neurochem.* **150**, 487–506, <https://doi.org/10.1111/jnc.14820>
- 164 Connor-Robson, N., Booth, H., Martin, J.G., Gao, B., Li, K., Doig, N. et al. (2019) An integrated transcriptomics and proteomics analysis reveals functional endocytic dysregulation caused by mutations in LRRK2. *Neurobiol. Dis.* **127**, 512–526, <https://doi.org/10.1016/j.nbd.2019.04.005>
- 165 Medeiros, A.T., Soll, L.G., Tessari, I., Bubacco, L. and Morgan, J.R. (2017)  $\alpha$ -Synuclein Dimers Impair Vesicle Fission During Clathrin-Mediated Synaptic Vesicle Recycling. *Front. Cell Neurosci.* **11**, 1–15, <https://doi.org/10.3389/fncel.2017.00388>
- 166 Kuboyama, T., Lee, Y.A., Nishiko, H. and Tohda, C. (2015) Inhibition of clathrin-mediated endocytosis prevents amyloid  $\beta$ -induced axonal damage. *Neurobiol. Aging* **36**, 1808–1819, <https://doi.org/10.1016/j.neurobiolaging.2015.02.005>
- 167 Gorenberg, E.L. and Chandra, S.S. (2017) The role of co-chaperones in synaptic proteostasis and neurodegenerative disease. *Front. Neurosci.* **11**, 1–16, <https://doi.org/10.3389/fnins.2017.00248>
- 168 Marchetti, B., Tirolo, C., L'Episcopo, F., Caniglia, S., Testa, N., Smith, J.A. et al. (2020) Parkinson's disease, aging and adult neurogenesis: Wnt/ $\beta$ -catenin signalling as the key to unlock the mystery of endogenous brain repair. *Aging Cell.* **19**, e13101, <https://doi.org/10.1111/acer.13101>
- 169 Onishi, K., Tian, R., Feng, B., Liu, Y., Wang, J., Li, Y. et al. (2020) LRRK2 mediates axon development by regulating Frizzled3 phosphorylation and growth cone-growth cone communication. *Proc. Natl. Acad. Sci. U.S.A.* **117**, 18037–18048, <https://doi.org/10.1073/pnas.1921878117>
- 170 Salašová, A., Yokota, C., Potěšil, D., Zdráhal, Z., Bryja, V. and Arenas, E. (2017) A proteomic analysis of LRRK2 binding partners reveals interactions with multiple signaling components of the WNT/PCP pathway. *Mol. Neurodegener.* **12**, 1–19, <https://doi.org/10.1186/s13024-017-0193-9>
- 171 Sancho, R.M., Law, B.M.H. and Harvey, K. (2009) Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways. *Hum. Mol. Genet.* **18**, 3955–3968, <https://doi.org/10.1093/hmg/ddp337>
- 172 Prasad, B.C. (2006) Wnt signaling establishes anteroposterior neuronal polarity and requires retromer in *C. elegans*. *Development* **133**, 1757–1766, <https://doi.org/10.1242/dev.02357>
- 173 Maro, G.S., Klassen, M.P. and Shen, K. (2009) A  $\beta$ -catenin-dependent Wnt pathway mediates anteroposterior axon guidance in *C. elegans* motor neurons. *PLoS One* **4**, <https://doi.org/10.1371/journal.pone.0004690>
- 174 Harterink, M., Kim, D.H., Middelkoop, T.C., Doan, T.D., van Oudenaarden, A. and Korswagen, H.C. (2011) Neuroblast migration along the anteroposterior axis of *C. elegans* is controlled by opposing gradients of Wnts and a secreted Frizzled-related protein. *Development* **138**, 2915–2924, <https://doi.org/10.1242/dev.064733>
- 175 Dusonchet, J., Li, H., Guillily, M., Liu, M., Stafa, K., Derada Troletti, C. et al. (2014) A Parkinson's disease gene regulatory network identifies the signaling protein RGS2 as a modulator of LRRK2 activity and neuronal toxicity. *Hum. Mol. Genet.* **23**, 4887–4905, <https://doi.org/10.1093/hmg/ddu202>
- 176 Fukuzono, T., Pastuhov, S.I., Fukushima, O., Li, C., Hattori, A., Iemura, Shun-ichiro et al. (2016) Chaperone complex BAG2-HSC70 regulates localization of *Caenorhabditis elegans* leucine-rich repeat kinase LRK-1 to the Golgi. *Genes Cells* **21**, 311–324, <https://doi.org/10.1111/gtc.12338>
- 177 Tomkins, J.E., Ferrari, R., Vavouraki, N., Hardy, J., Hardy, J., Hardy, J. et al. (2020) PINOT: An intuitive resource for integrating protein-protein interactions. *Cell Commun Signal.* **18**, 1–11, <https://doi.org/10.1186/s12964-020-00554-5>
- 178 Liu, Z., Bryant, N., Kumaran, R., Beilina, A., Abeliovich, A., Cookson, M.R. et al. (2018) LRRK2 phosphorylates membrane-bound Rabs and is activated by GTP-bound Rab7L1 to promote recruitment to the trans-Golgi network. *Hum. Mol. Genet.* **27**, 385–395, <https://doi.org/10.1093/hmg/ddx410>
- 179 Purylte, E., Dhekne, H.S., Sarhan, A.R., Gomez, R., Lis, P., Wightman, M. et al. (2018) Rab29 activation of the Parkinson's disease-associated LRRK2 kinase. *EMBO J.* **37**, 1–18, <https://doi.org/10.15252/embj.201798099>
- 180 Seol, W., Nam, D. and Son, I. (2019) Rab GTPases as physiological substrates of LRRK2 kinase. Vol. 28, Experimental Neurobiology. *Korean Soc. Neurodegenerative Dis.* 134–145
- 181 Beilina, A., Rudenko, I.N., Kaganovich, A., Civiero, L., Chau, H., Kalia, S.K. et al. (2014) Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. *Proc. Natl. Acad. Sci. U.S.A.* **111**, 2626–2631, <https://doi.org/10.1073/pnas.1318306111>
- 182 Madero-Pérez, J., Fernández, B., Lara Ordóñez, A.J., Fdez, E., Lobbstaal, E., Baekelandt, V. et al. (2018) RAB7L1-mediated relocalization of LRRK2 to the golgi complex causes centrosomal deficits via RAB8A. *Front. Mol. Neurosci.* **11**, 1–19, <https://doi.org/10.3389/fnmol.2018.00417>

- 183 Eguchi, T., Kuwahara, T., Sakurai, M., Komori, T., Fujimoto, T., Ito, G. et al. (2018) LRRK2 and its substrate Rab GTPases are sequentially targeted onto stressed lysosomes and maintain their homeostasis. *Proc. Natl. Acad. Sci. U.S.A.* **115**, E9115–E9124, <https://doi.org/10.1073/pnas.1812196115>
- 184 Fujimoto, T., Kuwahara, T., Eguchi, T., Sakurai, M., Komori, T. and Iwatsubo, T. (2017) Parkinson's disease-associated mutant LRRK2 phosphorylates Rab7L1 and modifies trans-Golgi morphology. *Biochem. Biophys. Res. Commun.* **495**, 1708–1715, <https://doi.org/10.1016/j.bbrc.2017.12.024>
- 185 Kalogeropoulou, A.F., Freemantle, J.B., Lis, P., Vides, E.G., Polinski, N.K. and Alessi, D.R. (2020) Endogenous Rab29 does not impact basal or stimulated LRRK2 pathway activity. *Biochem. J.* **0**, 4397–4423, <https://doi.org/10.1042/BCJ20200458>
- 186 Morris, C., Foster, O.K., Handa, S., Pelozo, K., Voss, L., Somhegyi, H. et al. (2018) Function and regulation of the *Caenorhabditis elegans* Rab32 family member GLO-1 in lysosome-related organelle biogenesis. *PLoS Genet.* **14**, 1–36, <https://doi.org/10.1371/journal.pgen.1007772>
- 187 Tucci, A., Nalls, M.A., Houlden, H., Revesz, T., Singleton, A.B., Wood, N.W. et al. (2010) Genetic variability at the PARK16 locus. *Eur. J. Hum. Genet.* **18**, 1356–1359, <https://doi.org/10.1038/ejhg.2010.125>
- 188 Vetter, I.R. and Wittinghofer, A. (2001) The guanine nucleotide-binding switch in three dimensions. *Science (80-)* **294**, 1299–1304, <https://doi.org/10.1126/science.1062023>
- 189 Kuwahara, T., Inoue, K., D'Agati, V.D., Fujimoto, T., Eguchi, T., Saha, S. et al. (2016) LRRK2 and RAB7L1 coordinately regulate axonal morphology and lysosome integrity in diverse cellular contexts. *Sci. Rep.* **6**, 1–12, <https://doi.org/10.1038/srep29945>
- 190 Aoki, Y., Manzano, R., Lee, Y., Dafinca, R., Aoki, M., Douglas, A.G.L. et al. (2017) C9orf72 and RAB7L1 regulate vesicle trafficking in amyotrophic lateral sclerosis and frontotemporal dementia. *Brain* **140**, 887–897, <https://doi.org/10.1093/brain/awx024>
- 191 Balendra, R. and Isaacs, A.M. (2018) C9orf72-mediated ALS and FTD: multiple pathways to disease. *Nat. Rev. Neurol.* **14**, 544–558, <https://doi.org/10.1038/s41582-018-0047-2>
- 192 Ferrari, R., Hernandez, D.G., Nalls, M.A., Rohrer, J.D., Ramasamy, A., Kwok, J.B.J. et al. (2014) Frontotemporal dementia and its subtypes: A genome-wide association study. *Lancet Neurol.* **13**, 686–699, [https://doi.org/10.1016/S1474-4422\(14\)70065-1](https://doi.org/10.1016/S1474-4422(14)70065-1)
- 193 Haile, Y., Deng, X., Ortiz-Sandoval, C., Tahbaz, N., Janowicz, A., Lu, J.Q. et al. (2017) Rab32 connects ER stress to mitochondrial defects in multiple sclerosis. *J. Neuroinflammation* **14**, 1–13, <https://doi.org/10.1186/s12974-016-0788-z>
- 194 Steger, M., Diez, F., Dhekne, H.S., Lis, P., Nirujogi, R.S., Karayel, O. et al. (2017) Systematic proteomic analysis of LRRK2-mediated rab GTPase phosphorylation establishes a connection to ciliogenesis. *Elife* **6**, 1–22, <https://doi.org/10.7554/eLife.31012>
- 195 Bultema, J.J. and Di Pietro, S.M. (2013) Cell type-specific Rab32 and Rab38 cooperate with the ubiquitous lysosome biogenesis machinery to synthesize specialized lysosome-related organelles. *Small GTPases* **4**, 16–21, <https://doi.org/10.4161/sgtp.22349>
- 196 Hermann, G.J., Schroeder, L.K., Hieb, C.A., Kershner, A.M., Rabbitts, B.M., Fonarev, P. et al. (2005) Genetic Analysis of Lysosomal Trafficking in *Caenorhabditis elegans*. *Mol. Biol. Cell.* **16**, 3273–3288, <https://doi.org/10.1091/mbc.e05-01-0060>
- 197 Grill, B., Bienvenut, W.V., Brown, H.M., Ackley, B.D., Quadroni, M. and Jin, Y. (2007) *C. elegans* RPM-1 Regulates Axon Termination and Synaptogenesis through the Rab GEF GLO-4 and the Rab GTPase GLO-1. *Neuron* **55**, 587–601, <https://doi.org/10.1016/j.neuron.2007.07.009>
- 198 Solano-Collado, V., Rofe, A. and Spanò, S. (2018) Rab32 restriction of intracellular bacterial pathogens. *Small GTPases* **9**, 216–223, <https://doi.org/10.1080/21541248.2016.1219207>
- 199 Wang, N., Wang, Z., Wang, C., Fu, X., Yu, G., Yue, Z. et al. (2018) Prediction of leprosy in the Chinese population based on a weighted genetic risk score. *PLoS Negl. Trop. Dis.* **12**, 1–12, <https://doi.org/10.1371/journal.pntd.0006789>
- 200 Herbst, S. and Gutierrez, M.G. (2019) LRRK2 in Infection: Friend or Foe? *ACS Infect. Dis.* **5**, 809–815, <https://doi.org/10.1021/acsinfecdis.9b00051>
- 201 Saunders-Pullman, R., Mirelman, A., Alcalay, R.N., Wang, C., Ortega, R.A., Raymond, D. et al. (2018) Progression in the LRRK2-Associated Parkinson disease population. *JAMA Neurol.* **75**, 312–319, <https://doi.org/10.1001/jamaneurol.2017.4019>
- 202 Fijarczyk, A. and Babik, W. (2015) Detecting balancing selection in genomes: Limits and prospects. *Mol. Ecol.* **24**, 3529–3545, <https://doi.org/10.1111/mec.13226>
- 203 McGrath, E., Waschbüsch, D., Baker, B.M. and Khan, A.R. (2019) LRRK2 binds to the Rab32 subfamily in a GTP-dependent manner via its armadillo domain. *Small GTPases* **00**, 1–14, <https://doi.org/10.1080/21541248.2019.1666623>
- 204 Waschbüsch, D., Hübel, N., Ossendorf, E., Lobbstaël, E., Baekelandt, V., Lindsay, A.J. et al. (2019) Rab32 interacts with SNX6 and affects retromer-dependent Golgi trafficking. *PLoS One* **14**, 1–18, <https://doi.org/10.1371/journal.pone.0208889>
- 205 Beilina, A., Bonet-Ponce, L., Kumaran, R., Kordich, J.J., Ishida, M., Mamais, A. et al. (2020) The Parkinson's Disease Protein LRRK2 Interacts with the GARP Complex to Promote Retrograde Transport to the trans-Golgi Network. *Cell Rep.* **31**, 107614, <https://doi.org/10.1016/j.celrep.2020.107614>
- 206 Zimprich, A., Benet-Pagès, A., Struhal, W., Graf, E., Eck, S.H., Offman, M.N. et al. (2011) A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset parkinson disease. *Am. J. Hum. Genet.* **89**, 168–175, <https://doi.org/10.1016/j.ajhg.2011.06.008>
- 207 Vilarinho-Güell, C., Wider, C., Ross, O.A., Dachsel, J.C., Kachergus, J.M., Lincoln, S.J. et al. (2011) VPS35 mutations in parkinson disease. *Am. J. Hum. Genet.* **89**, 162–167, <https://doi.org/10.1016/j.ajhg.2011.06.001>
- 208 Sharma, M., Ioannidis, J.P.A., Aasly, J.O., Annesi, G., Brice, A., Bertram, L. et al. (2012) A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. *J. Med. Genet.* **49**, 721–726, <https://doi.org/10.1136/jmedgenet-2012-101155>
- 209 Seaman, M.N.J., McCaffery, J.M. and Emr, S.D. (1998) A membrane coat complex essential for endosome-to-Golgi retrograde transport in yeast. *J. Cell Biol.* **142**, 665–681, <https://doi.org/10.1083/jcb.142.3.665>
- 210 Erro, R. (2015) VPS35 and EIF4G1 interactions and novel candidate genes for PD: From genes to pathways and back. *Mov. Disord.* **30**, 499–499, <https://doi.org/10.1002/mds.26187>
- 211 Tsika, E., Glauser, L., Moser, R., Fiser, A., Daniel, G., Sheerin, U.M. et al. (2014) Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration. *Hum. Mol. Genet.* **23**, 4621–4638, <https://doi.org/10.1093/hmg/ddu178>
- 212 Seaman, M.N.J., Marcusson, E.G., Cereghino, J.L. and Emr, S.D. (1997) Endosome to Golgi retrieval of the vacuolar protein sorting receptor, Vps10p, requires the function of the VPS29, VPS30, and VPS35 gene products. *J. Cell Biol.* **137**, 79–92, <https://doi.org/10.1083/jcb.137.1.79>



- 213 Coudreuse, D.Y.M., Roel, G., Betist, M.C., Destree, O. and Korswagen, H.C. (2006) Wnt Gradient Formation Requires Retromer Function in Wnt-Producing Cells. *Science (80-)* **312**, 921–925, <https://doi.org/10.1126/science.1124856>
- 214 Pan, C.L., Baum, P.D., Gu, M., Jorgensen, E.M., Clark, S.G. and Garriga, G. (2008) C. elegans AP-2 and Retromer Control Wnt Signaling by Regulating MIG-14/Wntless. *Dev. Cell.* **14**, 132–139, <https://doi.org/10.1016/j.devcel.2007.12.001>
- 215 Belenkaya, T.Y., Wu, Y., Tang, X., Zhou, B., Cheng, L., Sharma, Y.V. et al. (2008) The Retromer Complex Influences Wnt Secretion by Recycling Wntless from Endosomes to the Trans-Golgi Network. *Dev. Cell.* **14**, 120–131, <https://doi.org/10.1016/j.devcel.2007.12.003>
- 216 de Groot, R.E.A., Farin, H.F., Macůrková, M., van Es, J.H., Clevers, H.C. and Korswagen, H.C. (2013) Retromer Dependent Recycling of the Wnt Secretion Factor Wntless Is Dispensable for Stem Cell Maintenance in the Mammalian Intestinal Epithelium. *PLoS One* **8**, 1–9, <https://doi.org/10.1371/journal.pone.0076971>
- 217 Chiu, C.C., Weng, Y.H., Huang, Y.Z., Chen, R.S., Liu, Y.C., Yeh, T.H. et al. (2020) D620N VPS35 causes the impairment of Wnt/ $\beta$ -catenin signaling cascade and mitochondrial dysfunction in a PARK17 knockin mouse model. *Cell Death Dis.* **11**, 1–14, <https://doi.org/10.1038/s41419-020-03228-9>
- 218 Zhang, D., Isack, N.R., Glodowski, D.R., Liu, J., Chen, C.C.H., Shawn Xu, X.Z. et al. (2012) RAB-6.2 and the retromer regulate glutamate receptor recycling through a retrograde pathway. *J. Cell Biol.* **196**, 85–101, <https://doi.org/10.1083/jcb.201104141>
- 219 Munsie, L.N., Milnerwood, A.J., Seibler, P., Beccano-Kelly, D.A., Tatarnikov, I., Khinda, J. et al. (2015) Retromer-dependent neurotransmitter receptor trafficking to synapses is altered by the Parkinson's disease VPS35 mutation p.D620N. *Hum. Mol. Genet.* **24**, 1691–1703, <https://doi.org/10.1093/hmg/ddu582>
- 220 Chen, X., Kordich, J.K., Williams, E.T., Levine, N., Cole-Strauss, A., Marshall, L. et al. (2019) Parkinson's disease-linked D620N VPS35 knockin mice manifest tau neuropathology and dopaminergic neurodegeneration. *Proc. Natl. Acad. Sci. U. S. A.* **116**, 5765–5774
- 221 Carosi, J.M., Hein, L.K., van den Hurk, M., Adams, R., Milky, B., Singh, S. et al. (2020) Retromer regulates the lysosomal clearance of MAPT/tau. *Autophagy* **00**, 1–21, <https://doi.org/10.1080/15548627.2020.1821545>
- 222 Williams, E.T., Chen, X. and Moore, D.J. (2017) VPS35, the retromer complex and Parkinson's disease. *J Parkinsons Dis.* **7**, 219–233, <https://doi.org/10.3233/JPD-161020>
- 223 Small, S.A., Kent, K., Pierce, A., Leung, C., Kang, M.S., Okada, H. et al. (2005) Model-guided microarray implicates the retromer complex in Alzheimer's disease. *Ann. Neurol.* **58**, 909–919, <https://doi.org/10.1002/ana.20667>
- 224 Bhalla, A., Vetanovetz, C.P., Morel, E., Chamoun, Z., Di Paolo, G. and Small, S. (2012) Characterizing the location and trafficking routes of the neuronal retromer and its role in amyloid precursor protein transport. *Neurobiol. Dis.* **47**, 126–134, <https://doi.org/10.1016/j.nbd.2012.03.030>
- 225 Hardy, J. and Allsop, D. (1991) Amyloid deposition as the central event in the aetiology of Alzheimer's disease. *Trends Pharmacol. Sci. Elsevier Current Trends* **12**, 383–388, [https://doi.org/10.1016/0165-6147\(91\)90609-V](https://doi.org/10.1016/0165-6147(91)90609-V)
- 226 McDermott, J.B., Aamodt, S. and Aamodt, E. (1996) pti-1, a Caenorhabditis elegans gene whose products are homologous to the  $\tau$  microtubule-associated proteins. *Biochemistry* **35**, 9415–9423
- 227 Goedert, M., Baur, C.P., Ahringer, J., Jakes, R., Hasegawa, M., Spillantini, M.G. et al. (1996) PTL-1, a microtubule-associated protein with tau-like repeats from the nematode Caenorhabditis elegans. *J. Cell Sci.* **109**, 2661–2672
- 228 Chew, Y.L., Fan, X., Götze, J. and Nicholas, H.R. (2013) PTL-1 regulates neuronal integrity and lifespan in C. elegans. *J. Cell Sci.* **126**, 2079–2091, <https://doi.org/10.1242/jcs.jcs124404>
- 229 Pir, G.J., Choudhary, B., Mandelkow, E. and Mandelkow, E.M. (2016) Tau mutant A152T, a risk factor for FTD/PSP, induces neuronal dysfunction and reduced lifespan independently of aggregation in a C. elegans Tauopathy model. *Mol. Neurodegener.* **11**, 1–21, <https://doi.org/10.1186/s13024-016-0096-1>
- 230 Coppola, G., Chinnathambi, S., Lee, J.J.Y., Dombroski, B.A., Baker, M.C., Soto-ortolaza, A.I. et al. (2012) Evidence for a role of the rare p.A152T variant in mapt in increasing the risk for FTD-spectrum and Alzheimer's diseases. *Hum. Mol. Genet.* **21**, 3500–3512, <https://doi.org/10.1093/hmg/dds161>
- 231 Miyasaka, T., Shinzaki, Y., Yoshimura, S., Yoshina, S., Kage-Nakadai, E., Mitani, S. et al. (2018) Imbalanced expression of tau and tubulin induces neuronal dysfunction in C. elegans models of tauopathy. *Front. Neurosci.* **12**, 1–13, <https://doi.org/10.3389/fnins.2018.00415>
- 232 Butler, V.J., Salazar, D.A., Soriano-Castell, D., Alves-Ferreira, M., Dennissen, F.J.A., Vohra, M. et al. (2019) Tau/MAPT disease-associated variant A152T alters tau function and toxicity via impaired retrograde axonal transport. *Hum. Mol. Genet.* **28**, 1498–1514, <https://doi.org/10.1093/hmg/ddy442>
- 233 Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S.E., Dehejia, A., Dutra, A. et al. (1997) Mutation in the  $\alpha$ -synuclein gene identified in families with Parkinson's disease. *Science (80-)* **276**, 2045–2047, <https://doi.org/10.1126/science.276.5321.2045>
- 234 Iwai, A., Masliah, E., Yoshimoto, M., Ge, N., Flanagan, L., Rohan de Silva, H.A. et al. (1995) The precursor protein of non-A $\beta$  component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. *Neuron* **14**, 467–475, [https://doi.org/10.1016/0896-6273\(95\)90302-X](https://doi.org/10.1016/0896-6273(95)90302-X)
- 235 Compta, Y. and Revesz, T. (2020) Neuropathological and Biomarker Findings in Parkinson's Disease and Alzheimer's Disease: From Protein Aggregates to Synaptic Dysfunction. *J. Parkinsons Dis.* **8**, 1–16
- 236 Singleton, A. and Hardy, J. (2019) Progress in the genetic analysis of Parkinson's disease. *Hum. Mol. Genet.* **28**, R215–R218
- 237 Pihlström, L., Blauwendraat, C., Cappelletti, C., Berge-Seidl, V., Langmyhr, M., Henriksen, S.P. et al. (2018) A comprehensive analysis of SNCA-related genetic risk in sporadic parkinson disease. *Ann. Neurol.* **84**, 117–129, <https://doi.org/10.1002/ana.25274>
- 238 Chang, D., Nalls, M.A., Hallgrímsson, I.B., Hunkapiller, J., van der Brug, M., Cai, F. et al. (2017) A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci. *Nat. Genet.* **49**, 1511–1516, <https://doi.org/10.1038/ng.3955>
- 239 Bandres-Ciga, S., Saez-Atienzar, S., Kim, J.J., Makarios, M.B., Faghri, F., Diez-Fairen, M. et al. (2020) Large-scale pathway specific polygenic risk and transcriptomic community network analysis identifies novel functional pathways in Parkinson disease. *Acta Neuropathol.* **140**, 341–358, <https://doi.org/10.1007/s00401-020-02181-3>
- 240 Grenn, F.P., Kim, J.J., Makarios, M.B., Iwaki, H., Illarionova, A., Brolin, K. et al. (2020) The Parkinson's Disease Genome-Wide Association Study Locus Browser. *Mov. Disord.* **35**, 2056–2067, <https://doi.org/10.1002/mds.28197>

- 241 Xilouri, M., Brekk, O.R. and Stefanis, L. (2016) Autophagy and Alpha-Synuclein: Relevance to Parkinson's Disease and Related Synucleopathies. *Mov. Disord.* **31**, 178–192, <https://doi.org/10.1002/mds.26477>
- 242 Liu, J., Wang, X., Lu, Y., Duan, C., Gao, G., Lu, L. et al. (2017) Pink1 interacts with  $\alpha$ -synuclein and abrogates  $\alpha$ -synuclein-induced neurotoxicity by activating autophagy. *Cell Death Dis.* **8**, e3056, <https://doi.org/10.1038/cddis.2017.427>
- 243 da Fonseca, T.L., Pinho, R. and Outeiro, T.F. (2016) A familial ATP13A2 mutation enhances alpha-synuclein aggregation and promotes cell death. *Hum. Mol. Genet.* **25**, 2959–2971, <https://doi.org/10.1093/hmg/ddw147>
- 244 Miura, E., Hasegawa, T., Konno, M., Suzuki, M., Sugeno, N., Fujikake, N. et al. (2014) VPS35 dysfunction impairs lysosomal degradation of  $\alpha$ -synuclein and exacerbates neurotoxicity in a Drosophila model of Parkinson's disease. *Neurobiol. Dis.* **71**, 1–13, <https://doi.org/10.1016/j.nbd.2014.07.014>
- 245 Kamp, F., Exner, N., Lutz, A.K., Wender, N., Hegermann, J., Brunner, B. et al. (2010) Inhibition of mitochondrial fusion by  $\alpha$ -synuclein is rescued by PINK1, Parkin and DJ-1. *EMBO J.* **29**, 3571–3589, <https://doi.org/10.1038/emboj.2010.223>
- 246 Lakso, M., Vartiainen, S., Moilanen, A.M., Sirviö, J., Thomas, J.H., Nass, R. et al. (2003) Dopaminergic neuronal loss and motor deficits in *Caenorhabditis elegans* overexpressing human  $\alpha$ -synuclein. *J. Neurochem.* **86**, 165–172, <https://doi.org/10.1046/j.1471-4159.2003.01809.x>
- 247 Kuwahara, T., Koyama, A., Gengyo-Ando, K., Masuda, M., Kowa, H., Tsunoda, M. et al. (2006) Familial Parkinson mutant  $\alpha$ -synuclein causes dopamine neuron dysfunction in transgenic *Caenorhabditis elegans*. *J. Biol. Chem.* **281**, 334–340
- 248 Gaeta, A.L., Caldwell, K.A. and Caldwell, G.A. (2019) Found in translation: The utility of *C. elegans* Alpha-Synuclein models of Parkinson's disease. *Brain Sci.* **9**, 73, <https://doi.org/10.3390/brainsci9040073>
- 249 Jadiya, P., Fatima, S., Baghel, T., Mir, S.S. and Nazir, A. (2016) A Systematic RNAi Screen of Neuroprotective Genes Identifies Novel Modulators of Alpha-Synuclein-Associated Effects in Transgenic *Caenorhabditis elegans*. *Mol. Neurobiol.* **53**, 6288–6300, <https://doi.org/10.1007/s12035-015-9517-3>
- 250 Dues, D.J. and Moore, D.J. (2020) LRRK2 and Protein Aggregation in Parkinson's Disease: Insights From Animal Models. *Front. Neurosci.* **14**
- 251 Liu, G., Aliaga, L. and Cai, H. (2012)  $\alpha$ -synuclein, LRRK2 and their interplay in Parkinson's disease. *Future Neurol.* **7**, 145–153, <https://doi.org/10.2217/fnl.12.2>
- 252 Bae, E.-J., Kim, D.-K., Kim, C., Mante, M., Adame, A., Rockenstein, E. et al. (2018) LRRK2 kinase regulates  $\alpha$ -synuclein propagation via RAB35 phosphorylation. *Nat. Commun.* **9**, 3465, <https://doi.org/10.1038/s41467-018-05958-z>
- 253 Goedert, M., Jakes, R. and Spillantini, M.G. (2017) The Synucleinopathies: Twenty Years on. *J. Parkinsons Dis.* **7**, S53–S71, <https://doi.org/10.3233/JPD-179005>
- 254 Tyson, T., Senchuk, M., Cooper, J.F., George, S., Van Raamsdonk, J.M. and Brundin, P. (2017) Novel animal model defines genetic contributions for neuron-to-neuron transfer of  $\alpha$ -synuclein. *Sci. Rep.* **7**, 1–10, <https://doi.org/10.1038/s41598-017-07383-6>
- 255 Sharma, S., Trivedi, S., Pandey, T., Ranjan, S., Trivedi, M. and Pandey, R. (2021) Wedelolactone Mitigates Parkinsonism Via Alleviating Oxidative Stress and Mitochondrial Dysfunction Through NRF2/SKN-1. *Mol. Neurobiol.* **58**, 65–77
- 256 Pandey, T., Sammi, S.R., Nooreen, Z., Mishra, A., Ahmad, A., Bhatta, R.S. et al. (2019) Anti-ageing and anti-Parkinsonian effects of natural flavonol, tambulin from *Zanthoxylum armatum* promotes longevity in *Caenorhabditis elegans*. *Exp. Gerontol.* **120**, 50–61, <https://doi.org/10.1016/j.exger.2019.02.016>
- 257 Sharma, S., Bandopadhyay, R., Lashley, T., Renton, A.E.M., Kingsbury, A.E., Kumaran, R. et al. (2011) LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: A morphological and quantitative study. *Neuropathol. Appl. Neurobiol.* **37**, 777–790, <https://doi.org/10.1111/j.1365-2990.2011.01187.x>
- 258 Dickinson, D.J. and Goldstein, B. (2016) CRISPR-based methods for *caenorhabditis elegans* genome engineering. *Genetics* **202**, 885–901, <https://doi.org/10.1534/genetics.115.182162>
- 259 Jansen, I.E., Ye, H., Heetveld, S., Lechler, M.C., Michels, H., Seinstra, R.I. et al. (2017) Discovery and functional prioritization of Parkinson's disease candidate genes from large-scale whole exome sequencing. *Genome Biol.* **18**, 1–26, <https://doi.org/10.1186/s13059-017-1147-9>
- 260 Barstead, R., Moulder, G., Cobb, B., Frazee, S., Henthorn, D., Holmes, J. et al. (2012) Large-scale screening for targeted knockouts in the *caenorhabditis elegans* genome. *G3 Genes, Genomes, Genet.* **2**, 1415–1425
- 261 Vermilyea, S.C., Babinski, A., Tran, N., To, S., Guthrie, S., Kluss, J.H. et al. (2020) In Vitro CRISPR/Cas9-Directed Gene Editing to Model LRRK2 G2019S Parkinson's Disease in Common Marmosets. *Sci. Rep.* **10**, 3447, <https://doi.org/10.1038/s41598-020-60273-2>
- 262 Cabello, J., Sämann, J., Gómez-Orte, E., Erazo, T., Coppa, A., Pujol, A. et al. (2014) PDR-1/hParkin negatively regulates the phagocytosis of apoptotic cell corpses in *Caenorhabditis elegans*. *Cell Death Dis.* **5**, 1–11, <https://doi.org/10.1038/cddis.2014.57>
- 263 Anand, N., Holcom, A., Broussalian, M., Schmidt, M., Chinta, S.J., Lithgow, G.J. et al. (2020) Dysregulated iron metabolism in *C. elegans* catp-6/ATP13A2 mutant impairs mitochondrial function. *Neurobiol. Dis.* **139**, 104786, <https://doi.org/10.1016/j.nbd.2020.104786>
- 264 Civelek, M., Mehrkens, J.F., Carstens, N.M., Fitzenberger, E. and Wenzel, U. (2019) Inhibition of mitophagy decreases survival of *Caenorhabditis elegans* by increasing protein aggregation. *Mol. Cell. Biochem.* **452**, 123–131, <https://doi.org/10.1007/s11010-018-3418-5>
- 265 Cooper, J.F., Spielbauer, K.K., Senchuk, M.M., Nadarajan, S., Colaiacovo, M.P. and Van Raamsdonk, J.M. (2018)  $\alpha$ -synuclein expression from a single copy transgene increases sensitivity to stress and accelerates neuronal loss in genetic models of Parkinson's disease. *Exp. Neurol.* **310**, 58–69, <https://doi.org/10.1016/j.expneurol.2018.09.001>
- 266 Wu, S., Lei, L., Song, Y., Liu, M., Lu, S., Lou, D. et al. (2018) Mutation of hop-1 and pink-1 attenuates vulnerability of neurotoxicity in *C. elegans*: the role of mitochondria-associated membrane proteins in Parkinsonism. *Exp. Neurol.* **309**, 67–78, <https://doi.org/10.1016/j.expneurol.2018.07.018>
- 267 Springer, W., Hoppe, T., Schmidt, E. and Baumeister, R. (2005) A *Caenorhabditis elegans* Parkin mutant with altered solubility couples  $\alpha$ -synuclein aggregation to proteotoxic stress. *Hum. Mol. Genet.* **14**, 3407–3423, <https://doi.org/10.1093/hmg/ddi371>

- 268 Luz, A.L., Rooney, J.P., Kubik, L.L., Gonzalez, C.P., Song, D.H. and Meyer, J.N. (2015) Mitochondrial morphology and fundamental parameters of the mitochondrial respiratory chain are altered in *caenorhabditis elegans* strains deficient in mitochondrial dynamics and homeostasis processes. *PLoS One* **10**, 1–23, <https://doi.org/10.1371/journal.pone.0130940>
- 269 Chakraborty, S., Chen, P., Bornhorst, J., Schwerdtle, T., Schumacher, F., Kleuser, B. et al. (2015) Loss of pdr-1/parkin influences Mn homeostasis through altered ferroportin expression in *C. elegans*. *Metallomics* **7**, 847–856, <https://doi.org/10.1039/C5MT00052A>
- 270 Asikainen, S., Rudgalvyte, M., Heikkinen, L., Louhiranta, K., Lakso, M., Wong, G. et al. (2010) Global microRNA expression profiling of *caenorhabditis elegans* Parkinson's disease models. *J. Mol. Neurosci.* **41**, 210–218, <https://doi.org/10.1007/s12031-009-9325-1>
- 271 Erb, M.L. and Moore, D.J. (2020) LRRK2 and the Endolysosomal System in Parkinson's Disease. *J Parkinsons Dis.* **10**, 1271–1291, <https://doi.org/10.3233/JPD-202138>
- 272 Cogo, S., Manzoni, C., Lewis, P.A. and Greggio, E. (2020) Leucine-rich repeat kinase 2 and lysosomal dyshomeostasis in Parkinson disease. *J. Neurochem.* **152**, 273–283, <https://doi.org/10.1111/jnc.14908>
- 273 Orenstein, S.J., Kuo, S.H., Tasset, I., Arias, E., Koga, H., Fernandez-Carasa, I. et al. (2013) Interplay of LRRK2 with chaperone-mediated autophagy. *Nat. Neurosci.* **16**, 394–406, <https://doi.org/10.1038/nn.3350>
- 274 Chia, S.J., Tan, E.K. and Chao, Y.X. (2020) Historical perspective: Models of Parkinson's disease. *Int. J. Mol. Sci.* **21**, 1–14